<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Combination pharmacotherapy for the treatment of fibromyalgia in adults - Thorpe, J - 2018 | Cochrane Library</title> <meta content="Combination pharmacotherapy for the treatment of fibromyalgia in adults - Thorpe, J - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010585.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Combination pharmacotherapy for the treatment of fibromyalgia in adults - Thorpe, J - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010585.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD010585.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Combination pharmacotherapy for the treatment of fibromyalgia in adults" name="citation_title"/> <meta content="Joelle Thorpe" name="citation_author"/> <meta content="Queen's University" name="citation_author_institution"/> <meta content="Bonnie Shum" name="citation_author"/> <meta content="Queen's University" name="citation_author_institution"/> <meta content="R Andrew Moore" name="citation_author"/> <meta content="Philip J Wiffen" name="citation_author"/> <meta content="Ian Gilron" name="citation_author"/> <meta content="Queen's University" name="citation_author_institution"/> <meta content="gilroni@queensu.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="2" name="citation_issue"/> <meta content="10.1002/14651858.CD010585.pub2" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/02/19" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010585.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010585.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD010585.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="5-Hydroxytryptophan [therapeutic use]; Acetaminophen [therapeutic use]; Amitriptyline [therapeutic use]; Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Antidepressive Agents [therapeutic use]; Benzodiazepines [therapeutic use]; Carisoprodol [therapeutic use]; Drug Therapy, Combination [methods]; Duloxetine Hydrochloride [therapeutic use]; Fibromyalgia [*drug therapy]; Fluoxetine [therapeutic use]; Magnesium [therapeutic use]; Malates [therapeutic use]; Melatonin [therapeutic use]; Monoamine Oxidase Inhibitors [therapeutic use]; Muscle Relaxants, Central [therapeutic use]; Pregabalin [therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD010585.pub2&amp;doi=10.1002/14651858.CD010585.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="PrHmaMrX";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD010585\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD010585\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD010585.pub2",title:"Combination pharmacotherapy for the treatment of fibromyalgia in adults",firstPublishedDate:"Feb 19, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Pain, Palliative and Supportive Care Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010585.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010585.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD010585.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD010585.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010585.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD010585.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD010585.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD010585.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD010585.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD010585.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11866 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD010585.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0158"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0040"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-sec-0152"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/appendices#CD010585-sec-0169"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Combination pharmacotherapy for the treatment of fibromyalgia in adults</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#CD010585-cr-0004">Joelle Thorpe</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#CD010585-cr-0005">Bonnie Shum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#CD010585-cr-0006">R Andrew Moore</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#CD010585-cr-0007">Philip J Wiffen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information#CD010585-cr-0008"><i class="icon corresponding-author fa fa-envelope"></i>Ian Gilron</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information/en#CD010585-sec-0178">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 19 February 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD010585.pub2">https://doi.org/10.1002/14651858.CD010585.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD010585-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010585-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010585-abs-0011">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010585-abs-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010585-abs-0008">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010585-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD010585-abs-0001" lang="en"> <section id="CD010585-sec-0001"> <h3 class="title" id="CD010585-sec-0001">Background</h3> <p>Fibromyalgia is a chronic widespread pain condition affecting millions of people worldwide. Current pharmacotherapies are often ineffective and poorly tolerated. Combining different agents could provide superior pain relief and possibly also fewer side effects. </p> </section> <section id="CD010585-sec-0002"> <h3 class="title" id="CD010585-sec-0002">Objectives</h3> <p>To assess the efficacy, safety, and tolerability of combination pharmacotherapy compared to monotherapy or placebo, or both, for the treatment of fibromyalgia pain in adults. </p> </section> <section id="CD010585-sec-0003"> <h3 class="title" id="CD010585-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE, and Embase to September 2017. We also searched reference lists of other reviews and trials registries. </p> </section> <section id="CD010585-sec-0004"> <h3 class="title" id="CD010585-sec-0004">Selection criteria</h3> <p>Double‐blind, randomised controlled trials comparing combinations of two or more drugs to placebo or other comparators, or both, for the treatment of fibromyalgia pain. </p> </section> <section id="CD010585-sec-0005"> <h3 class="title" id="CD010585-sec-0005">Data collection and analysis</h3> <p>From all studies, we extracted data on: participant‐reported pain relief of 30% or 50% or greater; patient global impression of clinical change (PGIC) much or very much improved or very much improved; any other pain‐related outcome of improvement; withdrawals (lack of efficacy, adverse events), participants experiencing any adverse event, serious adverse events, and specific adverse events (e.g. somnolence and dizziness). The primary comparison was between combination and one or all single‐agent comparators. We also assessed the evidence using GRADE and created a 'Summary of findings' table. </p> </section> <section id="CD010585-sec-0006"> <h3 class="title" id="CD010585-sec-0006">Main results</h3> <p>We identified 16 studies with 1474 participants. Three studies combined a non‐steroidal anti‐inflammatory drug (NSAID) with a benzodiazepine (306 participants); two combined amitriptyline with fluoxetine (89 participants); two combined amitriptyline with a different agent (92 participants); two combined melatonin with an antidepressant (164 participants); one combined carisoprodol, paracetamol (acetaminophen), and caffeine (58 participants); one combined tramadol and paracetamol (acetaminophen) (315 participants); one combined malic acid and magnesium (24 participants); one combined a monoamine oxidase inhibitor with 5‐hydroxytryptophan (200 participants); and one combined pregabalin with duloxetine (41 participants). Six studies compared the combination of multiple agents with each component alone and with inactive placebo; three studies compared combination pharmacotherapy with each individual component but did not include an inactive placebo group; two studies compared the combination of two agents with only one of the agents alone; and three studies compared the combination of two or more agents only with inactive placebo. </p> <p>Heterogeneity among studies in terms of class of agents evaluated, specific combinations used, outcomes reported, and doses given prevented any meta‐analysis. None of the combinations of drugs found provided sufficient data for analysis compared with placebo or other comparators for our preferred outcomes. We therefore provide a narrative description of results. There was no or inadequate evidence in any comparison for primary and secondary outcomes. Two studies only reported any primary outcomes of interest (patient‐reported pain relief of 30%, or 50%, or greater). For each 'Risk of bias' item, only half or fewer of studies had unequivocal low risk of bias. Small size and selective reporting were common as high risk of bias. </p> <p>Our GRADE assessment was therefore very low for primary outcomes of pain relief of 30% or 50% or greater, PGIC much or very much improved or very much improved, any pain‐related outcome, participants experiencing any adverse event, any serious adverse event, or withdrawing because of an adverse event. </p> <p>Three studies found some evidence that combination pharmacotherapy reduced pain compared to monotherapy; these trials tested three different combinations: melatonin and amitriptyline, fluoxetine and amitriptyline, and pregabalin and duloxetine. Adverse events experienced by participants were not serious, and where they were reported (in 12 out of 16 studies), all participants experienced them, regardless of treatment. Common adverse events were nausea, dizziness, somnolence, and headache. </p> </section> <section id="CD010585-sec-0007"> <h3 class="title" id="CD010585-sec-0007">Authors' conclusions</h3> <p>There are few, large, high‐quality trials comparing combination pharmacotherapy with monotherapy for fibromyalgia, consequently limiting evidence to support or refute the use of combination pharmacotherapy for fibromyalgia. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD010585-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD010585-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD010585-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD010585-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD010585-abs-0009">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD010585-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD010585-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD010585-abs-0004">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD010585-abs-0002" lang="en"> <h3>Combinations of drugs versus single drugs to treat fibromyalgia pain in adults</h3> <p><b>Bottom line</b> </p> <p>There is no good evidence to prove or disprove that combining drugs is better than using single drugs for fibromyalgia. </p> <p><b>Background</b> </p> <p>People with fibromyalgia experience constant, widespread pain, sleep problems, and fatigue. Common drugs such as paracetamol (acetaminophen) and ibuprofen are not usually effective. Medicines used to treat epilepsy or depression can sometimes be effective for fibromyalgia and other forms of long‐lasting pain where there may be nerve damage. Many individuals with fibromyalgia take many different drugs to deal with pain. We did this review to find the evidence about using combinations of drugs compared to single drugs. </p> <p><b>Study characteristics</b> </p> <p>In September 2017 we searched for clinical trials where combinations of medicines were used for fibromyalgia pain in adults. We found 16 studies evaluating combinations of drugs versus one drug for fibromyalgia pain. </p> <p><b>Key results</b> </p> <p>These studies looked at combinations of all sorts of different drugs, but did not provide enough data to draw any conclusions. Many of the studies did not directly compare a combination of drugs with each single drug. They sometimes compared a combination of medicines with only one of the medicines in the combination, or with only placebo. This limited our ability to make any conclusions. </p> <p>Most studies did not report any of the outcomes important to people with fibromyalgia. Some studies showed that a combination of drugs is better at reducing pain than one drug alone, but other studies showed that one drug alone is better than a combination of drugs. Other studies did not find any difference between combinations of drugs and single drugs. </p> <p>Side effects were not severe, and generally were not different between combination therapy and monotherapy. </p> <p><b>Quality of the evidence</b> </p> <p>We rated the quality of the evidence from studies using four levels: very low, low, moderate, or high. Very low‐quality evidence means that we are very uncertain about the results. High‐quality evidence means that we are very confident in the results. Overall, the quality of evidence for important outcomes was very low. None of the combinations of drugs provided enough information for our preferred outcomes. We think that new studies will be very likely to change any conclusions drawn from these studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD010585-sec-0158" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD010585-sec-0158"></div> <h3 class="title" id="CD010585-sec-0159">Implications for practice</h3> <section id="CD010585-sec-0159"> <section id="CD010585-sec-0160"> <h5 class="title">For people with fibromyalgia</h5> <p>There are currently no pharmacotherapy options for fibromyalgia that sufficiently treat all symptoms while avoiding the risk of adverse events that could make fibromyalgia symptoms worse. Further research is necessary before determining if combinations of medications with different mechanisms of action can reduce fibromyalgia symptoms and cause fewer side effects than monotherapy. </p> </section> <section id="CD010585-sec-0161"> <h5 class="title">For clinicians</h5> <p>There are very few high‐quality clinical trials evaluating the efficacy of specific drug combinations for treating fibromyalgia, which precludes us from useful in‐depth meta‐analyses. As a result of this lack of data, clinical decisions about whether to treat fibromyalgia with monotherapy or combination pharmacotherapy may be based only on one or two double‐blind, randomised controlled trials and very small numbers of participants and events, depending on the drug combination in question. Individual studies point in different directions, to the superiority of combination therapy, to the superiority of monotherapy, or to no difference. In other words, whether or not combination pharmacotherapy is effective for treating fibromyalgia pain depends largely on the specific drugs under investigation, and generalisations are impossible. </p> <p>Using the GRADE approach to assess each study, evidence varied for different drug combinations and was very low quality. Reasons for evidence being determined as very low quality varied across studies and drug combinations but generally included lack of directness (i.e. comparing a combination to only one or even none of its single‐agent components), small sample sizes, short trial duration, and other statistical analysis issues. Taken together, available evidence does not allow us to draw firm conclusions about any of the combinations included in this review. </p> <p>Care should be taken when prescribing multimodal pharmacotherapy to ensure that adverse events are closely monitored and the risk for toxicity does not outweigh the potential benefits of combination therapy. Given some of the previous combinations studied, it should be emphasised that combining drugs that cause serotonin reuptake inhibition (e.g. amitriptyline, desipramine, duloxetine) with other serotonin reuptake inhibitors (e.g. tramadol) may cause ‘serotonin syndrome’ – a potentially fatal condition marked by altered mental status, hyperactivity, and neuromuscular dysfunction. It should also be noted that benzodiazepines are not recommended by the American Pain Society, the European League Against Rheumatism, or the Association of the Scientific Medical Societies in Germany for the treatment of fibromyalgia (<a href="./references#CD010585-bbs2-0079" title="HauserW , ThiemeK , TurkDC . Guidelines on the management of fibromyalgia syndrome - a systematic review. European Journal of Pain2010;14(1):5-10.">Hauser 2010</a>). </p> </section> <section id="CD010585-sec-0162"> <h5 class="title">For policy makers and funders of the intervention</h5> <p>Based on the results of this systematic review, there is currently insufficient evidence to support the routine use of any specific drug combination for the treatment of fibromyalgia pain. However, there is some evidence to support the use of combination therapy for fibromyalgia and real‐world studies indicate that various drug combinations are widely used for this condition. These observations and knowledge gaps point to a compelling need for new and improved research to identify: </p> <p> <ul id="CD010585-list-0009"> <li> <p>favourable combinations that could improve patient care outcomes and</p> </li> <li> <p>unfavourable combinations that are either associated with unacceptable adverse effects or cost‐ineffective for this condition. </p> </li> </ul> </p> </section> </section> <h3 class="title" id="CD010585-sec-0163">Implications for research</h3> <section id="CD010585-sec-0163"> <section id="CD010585-sec-0164"> <h5 class="title">General</h5> <p>Many of the studies meeting our inclusion criteria for this review had similar issues with small sample sizes, low power, short trial duration, and incomplete comparisons (for example, comparing a combination with placebo only, or comparing a combination of two drugs with only one of the drugs given as a monotherapy). These shortcomings prevent us from drawing strong conclusions about whether medications with different mechanisms of action can act additively or synergistically when given in combination. </p> <p>We suggest, as do many others (<a href="./references#CD010585-bbs2-0060" title="CalandreEP , Rico-VillademorosF , SlimM . An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy2015;16(9):1347-68.">Calandre 2015</a>; <a href="./references#CD010585-bbs2-0067" title="DaleR , StaceyB . Multimodal treatment of chronic pain. Medical Clinics of North America2016;100:55-64.">Dale 2016</a>; <a href="./references#CD010585-bbs2-0071" title="GerardiMC , BatticciottoA , TalottaR , Di FrancoM , AtzeniF , Sarzi-PuttiniP . Novel pharmaceutical options for treating fibromyalgia. Expert Review of Clinical Pharmacology2016;9(4):559-65.">Gerardi 2016</a>; <a href="./references#CD010585-bbs2-0076" title="HanC , Lee S-J, Seo H-J, Wang S-M, Park M-H, PatkarAA , et al. Available therapies and current management of fibromyalgia: focusing on pharmacologic agents. Drugs of Today2011;47(7):539-57.">Han 2011</a>), that more research is necessary. Given the compelling (but scant) evidence for combination pharmacotherapy found in several studies, future clinical trials evaluating combinations of the best‐tolerated and most effective treatments should be conducted. More studies testing the same types of combinations will enable meta‐analysis of multiple trials to determine which combinations (if any) are well‐tolerated and effective. As it stands, these issues have not been adequately addressed in the literature. </p> </section> <section id="CD010585-sec-0165"> <h5 class="title">Design</h5> <p>Special focus should be placed on designing studies that include treatment arms for the combination of two or more agents and for each individual agent in addition to a placebo arm (<a href="./references#CD010585-bbs2-0091" title="MeasePJ , SeymourK . Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?Current Pain and Headache Reports2008;12(6):399-405.">Mease 2008</a>). Including a placebo group will ensure that methods to quantify outcome measures have assay sensitivity to detect a treatment effect. Including each agent as a monotherapy will allow us to conclude whether the combination of two agents is superior to each agent alone, which will help answer the question of whether multiple medications can act synergistically or additively. Future studies should be planned with later meta‐analysis in mind. </p> <p>It is unclear whether radically different trial designs, such as that using an enriched‐enrolment, randomised withdrawal method would be appropriate for this clinical question, but it may be worth considering and has been used in fibromyalgia trials with some success (<a href="./references#CD010585-bbs2-0102" title="MooreRA , WiffenPJ , EcclestonC , DerryS , BaronR , BellRF , et al. Systematic review of enriched enrolment, randomised withdrawal trial designs in chronic pain: a new framework for design and reporting. Pain2015;156(8):1382-95. [DOI: 10.1097/j.pain.0000000000000088]">Moore 2015a</a>). A different approach to consider might be a more pragmatic design that acknowledges that there are considerable differences between individuals in terms of drug response, and that these are not predictable (<a href="./references#CD010585-bbs2-0096" title="MooreRA , DerryS , McQuayHJ , StraubeS , AldingtonD , WiffenP , et al. Clinical effectiveness: an approach to clinical trial design more relevant to clinical practice, acknowledging the importance of individual differences. Pain2010;149(2):173-6. [DOI: 10.1016/j.pain.2009.08.007]">Moore 2010c</a>). Such a design may be open to investigation of the effects of combinations in people with modest but inadequate response to one drug, mimicking an approach common in clinical practice. </p> </section> <section id="CD010585-sec-0166"> <h5 class="title">Measurement (endpoints)</h5> <p>Trials should report outcomes of known importance to people with fibromyalgia, such as pain scores and adverse events, and should also use several imputation methods for the large numbers who withdraw from treatment. </p> </section> <section id="CD010585-sec-0167"> <h5 class="title">Comparison between active treatments</h5> <p>Studies involving other treatments including non‐pharmacological interventions may be valuable in this context. A multi‐component approach reflects current practice. </p> </section> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD010585-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD010585-sec-0008"></div> <div class="table" id="CD010585-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with fibromyalgia </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> any combination of two or more drugs (note: our searches found nine combinations of drugs) </p> <p><b>Comparison:</b> placebo and/or other comparators </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Result</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>GRADE</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported pain relief of 30% or greater</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported pain relief of 50% or greater</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported global impression of clinical change much or very much improved (moderate improvement) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any pain‐related outcome indicating some improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD010585-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD010585-sec-0009"></div> <section id="CD010585-sec-0010"> <h3 class="title" id="CD010585-sec-0010">Description of the condition</h3> <p>Fibromyalgia is a complex, multisystem disorder characterised by a constellation of symptoms including chronic widespread pain lasting longer than three months, sleep disturbance, fatigue, irritable bowel syndrome, depressed mood and cognitive dysfunction. The severe and varied symptoms of fibromyalgia are reflected in functional disability and impaired quality of life (<a href="./references#CD010585-bbs2-0057" title="ArnoldLM , ClauwDJ , DuneganLJ , TurkDC , FibroCollaborative. A framework for fibromyalgia management for primary care providers. Mayo Clinic Proceedings2012;87(5):488-96.">Arnold 2012</a>; <a href="./references#CD010585-bbs2-0123" title="WolfeF . Fibromyalgia wars. Journal of Rheumatology2009;36(4):671-8.">Wolfe 2009</a>). While some rheumatologists have thought of fibromyalgia as a specific pain disorder, other investigators have characterised it as a bodily distress syndrome or a physical symptom disorder, or somatoform disorder (<a href="./references#CD010585-bbs2-0125" title="WolfeF , WalittBT , HauserW . What is fibromyalgia, how is it diagnosed and what does it really mean?Arthritis Care and Research2014;66(7):969-71.">Wolfe 2014</a>). It is a heterogeneous condition in which there is abnormal processing of the sensation of pain. The causes are not well understood, but it has features in common with neuropathic pain, including changes in the central nervous system. Moreover, people with neuropathic pain and people with fibromyalgia experience similar sensory phenomena (<a href="./references#CD010585-bbs2-0086" title="KoroschetzJ , RehmSE , GockelU , BroszM , FreynhagenR , TolleTR , et al. Fibromyalgia and neuropathic pain - differences and similarities. A comparison of 3057 patients with diabetic neuropathy and fibromyalgia. BMC Neurology2011;11(55):1-8.">Koroschetz 2011</a>). </p> <p>Fibromyalgia is highly prevalent, affecting 3% to 5% of the general population, with a female predominance (<a href="./references#CD010585-bbs2-0073" title="GranJT . The epidemiology of chronic generalized musculoskeletal pain. Best Practice &amp; Research. Clinical Rheumatology2003;17(4):547-61.">Gran 2003</a>; <a href="./references#CD010585-bbs2-0122" title="WolfeF , RossK , AndersonJ , RussellIJ , HebertL . The prevalence and characteristics of fibromyalgia in the general population. Arthritis and Rheumatism1995;38(1):19-28.">Wolfe 1995</a>). A recent estimate of global mean prevalence of fibromyalgia is 2.7%, with a mean in North America of 3.1%, in Europe of 2.5%, and in Asia of 1.7% (<a href="./references#CD010585-bbs2-0108" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):1-6.">Queiroz 2013</a>). However, estimates can vary depending on specific populations. For example, fibromyalgia prevalence is 9% in female textile workers in Turkey and 10% in metalworkers in Brazil (<a href="./references#CD010585-bbs2-0108" title="QueirozLP . Worldwide epidemiology of fibromyalgia. Current Pain and Headache Reports2013;17(8):1-6.">Queiroz 2013</a>), and as high as 22.2% in people diagnosed with migraine and 39% in people with low back pain (<a href="./references#CD010585-bbs2-0084" title="HüppeA , BrockowT , RaspeH . Chronic widespread pain and tender points in low back pain: a population-based study. Zeitschrift für Rheumatologie2004;63(1):76-83.">Hüppe 2004</a>). In addition to being personally devastating to the afflicted individual and his or her family, fibromyalgia also exerts a major adverse socioeconomic impact on society (e.g. see <a href="./references#CD010585-bbs2-0112" title="SilvermanS , DukesEM , JohnstonSS , BrandenburgNA , SadoskyA , HuseDM . The economic burden of fibromyalgia: comparative analysis with rheumatoid arthritis. Current Medical Research and Opinion2009;25(4):829-40.">Silverman 2009</a>; <a href="./references#CD010585-bbs2-0118" title="WhiteKP , SpeechleyM , HarthM , OstbyeT . The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada. Journal of Rheumatology1999;26(4):885-9.">White 1999</a>). </p> <p>Fibromyalgia pain is difficult to treat effectively, with only a minority of individuals experiencing a clinically relevant benefit from any one intervention. A multidisciplinary approach is now advocated, with pharmacological interventions being combined with physical or cognitive interventions, or both. In those treated with pharmacotherapy, the proportion of people who achieve worthwhile pain relief (at least a 50% reduction in pain intensity; <a href="./references#CD010585-bbs2-0099" title='MooreRA , StraubeS , AldingtonD . Pain measures and cut-offs - "no worse than mild pain" as a simple, universal outcome. Anaesthesia2013;68(4):400-12.'>Moore 2013a</a>) is generally only 10% to 25% more than with placebo, with numbers needed to treat for an additional beneficial outcome usually between 4 and 10 (<a href="./references#CD010585-bbs2-0119" title="WiffenPJ , DerryS , MooreRA , AldingtonD , ColeP , RiceASC , et al. Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews. Cochrane Database of Systematic Reviews2013, Issue 11. Art. No: CD010567. [DOI: 10.1002/14651858.CD010567.pub2]">Wiffen 2013</a>). Those who do experience good levels of pain relief, however, also benefit from substantial reductions in other symptoms, such as fatigue, function, impaired sleep, depression, anxiety, and impaired ability to work, with significant improvement in quality of life (<a href="./references#CD010585-bbs2-0094" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4.">Moore 2010a</a>; <a href="./references#CD010585-bbs2-0101" title="MooreRA , DerryS , TaylorRS , StraubeS , PhillipsCJ . The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain. Pain Practice2014;14(1):79-94.">Moore 2014</a>; <a href="./references#CD010585-bbs2-0115" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BioMed Central Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471-2474-12-125]">Straube 2011</a>). Fibromyalgia is not particularly different from other chronic pain in that only a small proportion of trial participants have a good response to treatment (<a href="./references#CD010585-bbs2-0100" title="MooreR , DerryS , EcclestonC , KalsoE . Expect analgesic failure; pursue analgesic success. BMJ2013;346:1-6.">Moore 2013b</a>). </p> </section> <section id="CD010585-sec-0011"> <h3 class="title" id="CD010585-sec-0011">Description of the intervention</h3> <p>Over the past 30 years, hundreds of randomised controlled trials have evaluated a wide variety of pharmacological interventions (e.g. NSAIDs, antidepressants, opioids and anticonvulsants) and non‐pharmacological interventions (e.g. exercise, acupuncture and cognitive behavioural therapy) for the treatment of various aspects of fibromyalgia (<a href="./references#CD010585-bbs2-0063" title="ClauwDJ . Fibromyalgia: a clinical review. JAMA2014;311(15):1547-55.">Clauw 2014</a>; <a href="./references#CD010585-bbs2-0072" title="GoldenbergDL , BurckhardtC , CroffordL . Management of fibromyalgia syndrome. JAMA2004;292(19):2388-95.">Goldenberg 2004</a>). In addition to exercise and cognitive behavioural therapy, pharmacotherapy remains an important and proven strategy for the management of fibromyalgia and its associated morbidities. However, adherence to most American College of Rheumatology‐recommended drugs is low, suggesting that many people with fibromyalgia are not satisfied with current pharmacotherapy options (<a href="./references#CD010585-bbs2-0088" title="LiuY , QianC , YangM . Treatment patterns associated with ACR-recommended medications in the management of fibromyalgia in the United States. Journal of Managed Care &amp; Specialty Pharmacy2016;22(3):263-71.">Liu 2016</a>). Indeed, current drugs reduce pain by only 25% to 40% on average and meaningful relief occurs in only 40% to 60%, in part due to incomplete drug efficacy and dose‐limiting adverse effects (<a href="./references#CD010585-bbs2-0077" title="HauserW , BernardyK , UceylerN , SommerC . Treatment of fibromyalgia syndrome with antidepressants: a meta-analysis. JAMA2009;301(2):198-209.">Hauser 2009a</a>; <a href="./references#CD010585-bbs2-0078" title="HauserW , BernardyK , UçeylerN , SommerC . Treatment of fibromyalgia syndrome with gabapentin and pregabalin--a meta-analysis of randomized controlled trials. Pain2009;145(1-2):69-81.">Hauser 2009b</a>; <a href="./references#CD010585-bbs2-0116" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BioMed Central Neurology2008;8:29.">Sultan 2008</a>). Several systematic reviews, using the outcome of at least 50% pain relief in longer‐term trials (8 to 14 weeks), indicate that drug‐specific response rates are low and numbers needed to treat for an additional beneficial outcome (NNTBs) are high; this is the case with pregabalin (<a href="./references#CD010585-bbs2-0069" title="DerryS , CordingM , WiffenPJ , LawS , PhillipsT , MooreRA . Pregabalin for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2016, Issue 9. Art. No: CD011790. [DOI: 10.1002/14651858.CD011790.pub2]">Derry 2016</a>), gabapentin (<a href="./references#CD010585-bbs2-0065" title="CooperTE , DerryS , WiffenPJ , MooreRA . Gabapentin for fibromyalgia pain in adults. Cochrane Database of Systematic Reviews2017, Issue 1. Art. No: CD012188. [DOI: 10.1002/14651858.CD012188.pub2]">Cooper 2017</a>), milnacipran (<a href="./references#CD010585-bbs2-0066" title="CordingM , DerryS , PhillipsT , MooreRA , WiffenPJ . Milnacipran for pain in fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 10. Art. No: CD008244. [DOI: 10.1002/14651858.CD008244.pub3]">Cording 2015</a>), duloxetine (<a href="./references#CD010585-bbs2-0089" title="LunnMP , HughesRA , WiffenPJ . Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database of Systematic Reviews2009, Issue 4. Art. No: CD007115. [DOI: 10.1002/14651858.CD007115]">Lunn 2009</a>; <a href="./references#CD010585-bbs2-0116" title="SultanA , GaskellH , DerryS , MooreRA . Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials. BioMed Central Neurology2008;8:29.">Sultan 2008</a>) and amitriptyline (<a href="./references#CD010585-bbs2-0103" title="MooreRA , DerryS , AldingtonD , ColeP , WiffenPJ . Amitriptyline for fibromyalgia in adults. Cochrane Database of Systematic Reviews2015, Issue 7. Art. No: CD011824. [DOI: 10.1002/14651858.CD011824]">Moore 2015b</a>). For many drugs, the evidence is limited and does not show any obvious benefit, for example with lacosamide (<a href="./references#CD010585-bbs2-0080" title="HearnL , DerryS , MooreRA . Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database of Systematic Reviews2012, Issue 2. Art. No: CD009318. [DOI: 10.1002/14651858.CD009318.pub2]">Hearn 2012</a>). The importance of the outcome of at least 50% pain relief is that good pain reduction also results in improved sleep, fatigue, depression, symptoms, quality of life and work (<a href="./references#CD010585-bbs2-0094" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4.">Moore 2010a</a>; <a href="./references#CD010585-bbs2-0115" title="StraubeS , MooreRA , PaineJ , DerryS , PhillipsCJ , HallierE , et al. Interference with work in fibromyalgia: effect of treatment with pregabalin and relation to pain response. BioMed Central Musculoskeletal Disorders2011;12:125. [DOI: 10.1186/1471-2474-12-125]">Straube 2011</a>). It is also what people with fibromyalgia want from treatment (<a href="./references#CD010585-bbs2-0106" title="O'BrienEM , StaudRM , HassingerAD , McCullochRC , CraggsJG , AtchisonJW , et al. Patient-centered perspective on treatment outcomes in chronic pain. Pain Medicine2010;11(1):6-15.">O'Brien 2010</a>). </p> <p>These limitations in clinical practice have led some to hypothesise that a combination of different analgesic drugs acting through different mechanisms may provide superior outcomes compared to monotherapy (<a href="./references#CD010585-bbs2-0091" title="MeasePJ , SeymourK . Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?Current Pain and Headache Reports2008;12(6):399-405.">Mease 2008</a>). Combining analgesics has proven to produce additive effects in acute pain (<a href="./references#CD010585-bbs2-0097" title="MooreRA , DerryCJ , DerryS , StraubeS , McQuayHJ . A conservative method of testing whether combination analgesics produce additive or synergistic effects using evidence from acute pain and migraine. European Journal of Pain2012;16(4):585-91.">Moore 2012a</a>) and possibly also in neuropathic pain (<a href="./references#CD010585-bbs2-0062" title="ChaparroLE , WiffenPJ , MooreRA , GilronI . Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database of Systematic Reviews2012, Issue 7. Art. No: CD008943. [DOI: 10.1002/14651858.CD008943.pub2]">Chaparro 2012</a>). </p> </section> <section id="CD010585-sec-0012"> <h3 class="title" id="CD010585-sec-0012">How the intervention might work</h3> <p>When given as monotherapy, most drugs for fibromyalgia often have intrinsic limitations in their analgesic efficacy, dose‐limiting side effects, or both. Combining two or more drugs with different pharmacological mechanisms has the potential to provide additive or possibly even synergistic effects in pain reduction, producing superior outcomes compared to monotherapy, provided that there is less additivity in terms of drug side effects in the combination. </p> </section> <section id="CD010585-sec-0013"> <h3 class="title" id="CD010585-sec-0013">Why it is important to do this review</h3> <p>The appealing rationale for combination pharmacotherapy has led to the practice of polypharmacy in clinical practice. Data indicate that at least 34% of people with fibromyalgia are being prescribed two or more analgesic medications at the same time (<a href="./references#CD010585-bbs2-0058" title="BergerA , DukesE , MartinS , EdelsbergJ , OsterG . Characteristics and healthcare costs of patients with fibromyalgia syndrome. International Journal of Clinical Practice2007;61(9):1498-508.">Berger 2007</a>). However, given the potential for both pain reduction and drug side effects to be compounded in a drug combination, rigorous combination‐specific evidence must exist in order to provide a rationale for the practice of combination pharmacotherapy. The question of whether using two or more drugs together really is better than using any one alone also needs to be answered. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD010585-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD010585-sec-0014"></div> <p>To assess the efficacy, safety, and tolerability of combination pharmacotherapy compared to monotherapy or placebo, or both, for the treatment of fibromyalgia pain in adults. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD010585-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD010585-sec-0015"></div> <section id="CD010585-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD010585-sec-0017"> <h4 class="title">Types of studies</h4> <p>Double‐blind, randomised controlled studies comparing combinations of two or more drugs to placebo or at least one other comparator, or both, for the treatment of fibromyalgia pain. Studies must include pain assessment as a primary or secondary outcome. We required full journal publications or summary clinical trial reports, and excluded brief abstracts. We also excluded non‐randomised studies, case reports and other clinical observations. </p> </section> <section id="CD010585-sec-0018"> <h4 class="title">Types of participants</h4> <p>Adult participants (18 years and older) with a diagnosis of fibromyalgia.</p> </section> <section id="CD010585-sec-0019"> <h4 class="title">Types of interventions</h4> <p>Combinations of two or more different drugs administered by any route.</p> </section> <section id="CD010585-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>Studies needed to report pain assessment as either the primary or secondary outcome.</p> <p>We anticipated that a variety of outcome measures would have been used in the studies. We expected that the majority of studies would use standard subjective scales for pain intensity or pain relief, or both, and we paid particular attention to the Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) definitions for moderate and substantial benefit in chronic pain studies (<a href="./references#CD010585-bbs2-0070" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21.">Dworkin 2008</a>). These are defined as at least 30% pain relief over baseline (moderate), at least 50% pain relief over baseline (substantial), much or very much improved on Patient Global Impression of Change (PGIC) (moderate) and very much improved on PGIC (substantial). </p> <section id="CD010585-sec-0021"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD010585-list-0001"> <li> <p>Patient‐reported pain relief of 30% or greater</p> </li> <li> <p>Patient‐reported pain relief of 50% or greater</p> </li> <li> <p>Patient‐reported global impression of clinical change (PGIC) much or very much improved</p> </li> <li> <p>Patient‐reported global impression of clinical change (PGIC) very much improved</p> </li> </ul> </p> </section> <section id="CD010585-sec-0022"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD010585-list-0002"> <li> <p>Any pain‐related outcome indicating some improvement</p> </li> <li> <p>Participants experiencing any adverse event</p> </li> <li> <p>Participants experiencing any serious adverse event</p> </li> <li> <p>Withdrawals due to adverse events</p> </li> <li> <p>Withdrawals due to lack of efficacy</p> </li> <li> <p>Specific adverse events, particularly somnolence and dizziness</p> </li> </ul> </p> </section> </section> </section> <section id="CD010585-sec-0023"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD010585-sec-0024"> <h4 class="title">Electronic searches</h4> <p>We searched the following databases for studies:</p> <p> <ul id="CD010585-list-0003"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL Issue 8 of 12, 2017, via <i>The Cochrane Library</i>) </p> </li> <li> <p>MEDLINE &amp; MEDLINE in Process (via Ovid) 1946 to 5/9/17;</p> </li> <li> <p>Embase (via Ovid) 1974 to 2017 week 36.</p> </li> </ul> </p> <p>The search strategies used can be found in <a href="./appendices#CD010585-sec-0170">Appendix 1</a>. There were no language or date restrictions applied to the searches. </p> </section> <section id="CD010585-sec-0025"> <h4 class="title">Searching other resources</h4> <p>We searched ISCRTN Registry (https://www.isrctn.com), and clinicaltrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) in September 2017 and the WHO International Clinical Trials Registry Platform (ICTRP) (<a href="http://apps.who.int/trialsearch/" target="_blank">apps.who.int/trialsearch/</a>) in September 2017 to identify additional completed or ongoing studies. We also searched the reference lists of published reviews on the subject of fibromyalgia pharmacotherapy for eligible clinical trials. </p> </section> </section> <section id="CD010585-sec-0026"> <h3 class="title" id="CD010585-sec-0026">Data collection and analysis</h3> <section id="CD010585-sec-0027"> <h4 class="title">Selection of studies</h4> <p>We determined study eligibility by reading each study identified by the search. Two review authors read all citations independently and reached agreement by discussion. We did not anonymise the studies before assessment. </p> </section> <section id="CD010585-sec-0028"> <h4 class="title">Data extraction and management</h4> <p>Two review authors (JT and IG) extracted data using a standard form and double‐checked for agreement before entry into Review Manager 5 (RevMan 5) or completing any other analysis (<a href="./references#CD010585-bbs2-0109" title="Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">RevMan 2014</a>). We included information about the pain condition and number of participants treated, drugs and dosing regimens, study design (placebo or active control), study duration and follow‐up, analgesic outcome measures and results, withdrawals and adverse events (participants experiencing any adverse event or serious adverse event). </p> </section> <section id="CD010585-sec-0029"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JT and IG) independently assessed risk of bias for each study, using the criteria outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010585-bbs2-0082" title="HigginsJPT , AltmanDG , Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Higgins 2011a</a>), and adapted from those used by Cochrane Pregnancy and Childbirth, with any disagreements resolved by discussion. We assessed the following for each study. </p> <p> <ul id="CD010585-list-0004"> <li> <p>Random sequence generation (checking for possible selection bias). We assessed the method used to generate the allocation sequence as: low risk of bias (i.e. any truly random process, for example random number table; computer random number generator); unclear risk of bias (when the method used to generate the sequence is not clearly stated). We excluded studies at a high risk of bias that used a non‐random process (for example, odd or even date of birth; hospital or clinic record number). </p> </li> <li> <p>Allocation concealment (checking for possible selection bias). The method used to conceal allocation to interventions prior to assignment determines whether intervention allocation could have been foreseen in advance of, or during recruitment, or changed after assignment. We assessed the methods as: low risk of bias (for example, telephone or central randomisation; consecutively numbered, sealed, opaque envelopes); unclear risk of bias (when method is not clearly stated). We excluded studies that did not conceal allocation and were therefore at a high risk of bias (for example, open list). </p> </li> <li> <p>Blinding of participants and personnel (checking for possible performance bias). We assessed the methods used to blind study participants and outcome assessors from knowledge of which intervention a participant received. We assessed the methods as: low risk of bias (e.g. study states that it was blinded and describes the method used to achieve blinding, for example, identical tablets, matched in appearance and smell); or unclear risk of bias (study states that it was blinded but does not provide an adequate description of how it was achieved). We excluded studies at a high risk of bias that were not double‐blind. </p> </li> <li> <p>Blinding of outcome assessment (checking for possible detection bias). We assessed the methods used to blind outcome assessors as to which intervention participants received. We assessed the methods as: low risk of bias (e.g. study states that data collectors were blinded to allocation, or outcome measures being assessed were objective and not subject to bias); or unclear risk of bias (it was unclear and not stated anywhere that the outcome assessors were blinded to treatment allocation). We excluded studies with a high risk of bias for outcome assessment. </p> </li> <li> <p>Incomplete outcome data (checking for possible attrition bias due to the amount, nature, and handling of incomplete outcome data). We assessed the methods used to deal with incomplete data as: low risk of bias (i.e. less than 10% of participants did not complete the study or used ‘baseline observation carried forward’ (BOCF) analysis, or both); unclear risk of bias (used ‘last observation carried forward' (LOCF) analysis); or high risk of bias (used ‘completer’ analysis). </p> </li> <li> <p>Selective reporting (checking for possible reporting bias). We assessed studies for reporting bias by determining how closely the published reports matched with protocols on registered databases. We assessed this as: low risk of bias (study protocol was registered and all outcomes listed appeared in the published report); unclear risk of bias (study protocol was not registered so no assessment could be made); or high risk of bias (study protocol was registered and there were some discrepancies between outcomes in the protocol and the published report). </p> </li> <li> <p>Size of study (checking for possible biases confounded by small size). We assessed studies as being at low risk of bias (i.e. 200 participants or more per treatment arm); unclear risk of bias (50 to 199 participants per treatment arm); or high risk of bias (fewer than 50 participants per treatment arm). Small studies have been shown to overestimate treatment effects, probably because the conduct of small studies is more likely to be less rigorous, allowing critical criteria to be compromised (<a href="./references#CD010585-bbs2-0068" title="DechartresA , TrinquartL , BoutronI , RavaudP . Influence of trial sample size on treatment effect estimates: meta-epidemiological study. BMJ2013;346:f2304. [DOI: 10.1136/bmj.f2304]">Dechartres 2013</a>; <a href="./references#CD010585-bbs2-0105" title="NüeschE , TrelleS , ReichenbachS , RutjesAW , TschannenB , AltmanDG , et al. Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ2010;341:c3515. [DOI: 10.1136/bmj.c3515]">Nüesch 2010</a>). </p> </li> <li> <p>Trial duration (checking for possible biases confounded by short trial lengths). We assessed studies as being at low risk of bias (at least seven weeks' duration); unclear risk of bias (three to six weeks' duration); or high risk of bias (less than three weeks' duration). </p> </li> <li> <p>Similarities of baseline characteristics. We assessed studies as being at low risk of bias (no statistically significant differences in baseline measures of sex ratio, average age, or pain scores between groups); unclear risk of bias (no statistical comparison reported in baseline measures of sex ratio, average age, and/or pain scores between groups); high risk of bias (there was a statistical difference between groups at baseline for sex ratio, average age, and/or pain scores). </p> </li> </ul> </p> </section> <section id="CD010585-sec-0030"> <h4 class="title">Measures of treatment effect</h4> <p>The primary comparison of interest was between the combination of study drug(s) and any or all single‐agent comparators. We also considered comparisons of each drug combination and any other placebo or active treatment comparators, or both. We planned to combine studies if they evaluated the same drug class combination at roughly similar doses and durations of treatment. We planned to perform any analyses of study data for binary outcomes using RevMan 5. </p> <p>We planned to calculate NNTB as the reciprocal of the absolute risk reduction (ARR) (<a href="./references#CD010585-bbs2-0090" title="McQuayH , MooreR . An Evidence-based Resource for Pain Relief. Oxford: Oxford University Press, 1998. [ISBN: 0-19-263048-2]">McQuay 1998</a>). For unwanted effects, this number becomes the number needed to treat for an additional harmful outcome (NNTH) and is calculated in the same manner. We planned to use dichotomous data to calculate risk ratio (RR) with 95% confidence intervals (CI) using a fixed‐effect model unless we found significant statistical heterogeneity. We did not plan to use continuous data in any analyses. </p> </section> <section id="CD010585-sec-0031"> <h4 class="title">Unit of analysis issues</h4> <p>In studies involving more than one active treatment group, we planned to divide the control treatment group among active treatment arms. </p> </section> <section id="CD010585-sec-0032"> <h4 class="title">Dealing with missing data</h4> <p>We planned to use intention‐to‐treat (ITT) analysis where the ITT population consisted of participants who were randomised, took at least one dose of the assigned study medication and provided at least one post‐baseline assessment. Missing participants were to be assigned zero improvement. </p> </section> <section id="CD010585-sec-0033"> <h4 class="title">Assessment of heterogeneity</h4> <p>We planned to only combine studies evaluating similar conditions for analysis, so as to avoid clinical heterogeneity. We planned to use visual data assessment with L'Abbé plots (<a href="./references#CD010585-bbs2-0087" title="L’AbbéKA , DetskyAS , O’RourkeK . Meta-analysis in clinical research. Annals of Internal Medicine1987;107:224-33.">L'Abbé 1987</a>) and calculation of the I² statistic (<a href="./references#CD010585-bbs2-0081" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analyses. BMJ2003;327:557-60.">Higgins 2003</a>) to explore statistical heterogeneity when the I² statistic was greater than 50%. </p> </section> <section id="CD010585-sec-0034"> <h4 class="title">Assessment of reporting biases</h4> <p>The aim of this review was to use dichotomous data of known utility (<a href="./references#CD010585-bbs2-0094" title="MooreRA , StraubeS , PaineJ , PhillipsCJ , DerryS , McQuayHJ . Fibromyalgia: moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain. Pain2010;149(2):360-4.">Moore 2010a</a>). The review did not depend on what authors of the original studies chose to report or not, though we anticipated difficulties with studies failing to report any dichotomous results. We extracted continuous data, which probably poorly reflect efficacy and utility, and therefore used them for illustrative purposes only. We planned to undertake assessment of publication bias using a method designed to detect the amount of unpublished data with a null effect required to make any result clinically irrelevant (usually taken to mean a NNTB or NNTH of 10 or higher) (<a href="./references#CD010585-bbs2-0093" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> </section> <section id="CD010585-sec-0035"> <h4 class="title">Data synthesis</h4> <p>We planned to use a fixed‐effect model for any conducted meta‐analyses. However, if it were deemed appropriate to combine heterogeneous studies, we planned to use a random‐effects model. </p> <p>At least 200 participants would have to be available for any outcome before we pooled studies (<a href="./references#CD010585-bbs2-0092" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>). Where appropriate we used or calculated risk ratio (RR) or risk difference (RD) with 95% confidence intervals (CI) using a fixed‐effect model (<a href="./references#CD010585-bbs2-0104" title="MorrisJA , GardnerMJ . Calculating confidence intervals for relative risk, odds ratios and standardised ratios and rates. In: GardnerMJ , AltmanDG , editors(s). Statistics with Confidence - Confidence Intervals and Statistical Guidelines. London: British Medical Journal, 1995:50-63.">Morris 1995</a>). We used or calculated NNTB and NNTH with 95% CIs using the pooled number of events, using the method devised by Cook and Sackett (<a href="./references#CD010585-bbs2-0064" title="CookRJ , SackettDL . The number needed to treat: a clinically useful measure of treatment effect. BMJ (Clinical Research Ed)1995;310:452-4.">Cook 1995</a>). We assumed a statistically significant difference from control when the 95% CI of the RR did not include 1 or the RD, 0. </p> <section id="CD010585-sec-0036"> <h5 class="title">Quality of the evidence</h5> <p>We used the GRADE approach to assess the quality of evidence related to each of the key outcomes, and reported our judgement on the quality of the evidence in the 'Summary of findings' table (<a href="./references#CD010585-bbs2-0111" title="SchünemannHJ , OxmanAD , VistGE , HigginsJPT , DeeksJJ , GlasziouP , et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011b</a>; <a href="./appendices#CD010585-sec-0174">Appendix 2</a>). We assessed potential for publication bias, based on the amount of unpublished data required to make the result clinically irrelevant (<a href="./references#CD010585-bbs2-0093" title="MooreRA , BardenJ , DerryS , McQuayHJ . Managing potential publication bias. In: McQuayHJ , KalsoE , MooreRA , editors(s). Systematic Reviews in Pain Research: Methodology Refined. Seattle: IASP Press, 2008:15-24. [ISBN: 978–0–931092–69–5]">Moore 2008</a>). </p> <p>We decreased the grade rating by one (‐1) or two (‐2) (up to a maximum of ‐3 to 'very low') if we identified: </p> <p> <ul id="CD010585-list-0005"> <li> <p>serious (‐1) or very serious (‐2) limitation to study quality;</p> </li> <li> <p>important inconsistency (‐1);</p> </li> <li> <p>some (‐1) or major (‐ 2) uncertainty about directness;</p> </li> <li> <p>imprecise or sparse data (‐1);</p> </li> <li> <p>high probability of reporting bias (‐1).</p> </li> </ul> </p> <p>In addition, there may be other circumstances where the overall rating for a particular outcome needs to be adjusted as recommended by GRADE guidelines (<a href="./references#CD010585-bbs2-0074" title="GuyattG , OxmanAD , SultanS , BrozekJ , GlasziouP , Alonso-CoelloP , et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. Journal of Clinical Epidemiology2013;66(2):151-7. [DOI: 10.1016/j.jclinepi.2012.01.006]">Guyatt 2013a</a>). For example, if there were so few data that the results were highly susceptible to the random play of chance, or if a study used LOCF imputation in circumstances where there were substantial differences in adverse event withdrawals, one would have no confidence in the result, and would need to downgrade the quality of the evidence by three levels, to very low quality. In circumstances where there were no data reported for an outcome, we would report the level of evidence as very low quality (<a href="./references#CD010585-bbs2-0075" title="GuyattGH , OxmanAD , SantessoN , HelfandM , VistG , KunzR , et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. Journal of Clinical Epidemiology2013;66(2):158-72. [DOI: 10.1016/j.jclinepi.2012.01.012]">Guyatt 2013b</a>). </p> </section> <section id="CD010585-sec-0037"> <h5 class="title">'Summary of findings' table</h5> <p>We included a 'Summary of findings' table as set out in the Cochrane Pain, Palliative and Supportive Care (PaPaS) author guide (<a href="./references#CD010585-bbs2-0107" title="Cochrane Pain, Palliative and Supportive Care Group. PaPaS Author and Referee Guidance. papas.cochrane.org/papas-documents Accessed 29 August 2016.">PaPaS 2012</a>), and recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD010585-bbs2-0110" title="SchünemannHJ , OxmanAD , HigginsJPT , VistGE , GlasziouP , GuyattGH . Chapter 11: Presenting results and ‘Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.">Schünemann 2011a</a>). We planned to include, where possible, outcomes equivalent to moderate or substantial benefit of at least 30% and at least 50% pain‐intensity reduction, PGIC (at least moderate improvement) (<a href="./references#CD010585-bbs2-0070" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. Journal of Pain2008;9(2):105-21.">Dworkin 2008</a>), any pain‐related outcome indicating some improvement, participants experiencing any adverse event, participants experiencing any serious adverse event, and withdrawals due to adverse events. </p> </section> </section> <section id="CD010585-sec-0038"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We grouped studies according to specific combinations of drug classes (e.g. opioids and anticonvulsants). </p> </section> <section id="CD010585-sec-0039"> <h4 class="title">Sensitivity analysis</h4> <p>We did not plan any sensitivity analyses because the evidence base was known to be too small to allow reliable analysis. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD010585-sec-0040" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD010585-sec-0040"></div> <section id="CD010585-sec-0041"> <h3 class="title">Description of studies</h3> <section id="CD010585-sec-0042"> <h4 class="title">Results of the search</h4> <p>After excluding duplicates, we identified 723 citations using the search criteria outlined in the protocol. Two authors (IG and JT) independently applied the inclusion/exclusion criteria to all 723 citations, resulting in 57 studies that we scrutinised in more detail. Of these 57 citations, 16 studies fulfilled the inclusion criteria for this review (<a href="#CD010585-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD010585-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Flow diagram" data-id="CD010585-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> </div> <p>We searched <a href="http://clinicaltrials.gov" target="_blank">clinicaltrials.gov</a>, <a href="http://controlled-trials.com" target="_blank">controlled-trials.com</a>, and the WHO International Clinical Trials Registry Platform for ongoing or recently completed combination fibromyalgia studies using a comparable search strategy. This search only resulted in three potentially relevant studies (<a href="./references#CD010585-bbs2-0054" title="Lidocaine on manifestations of fibromyalgia (LIMAFIBRO). Ongoing study. January 2005. Contact author for more information.">NCT00991848</a>; <a href="./references#CD010585-bbs2-0055" title="Study to assess the clinical benefit of droxidopa and droxidopa/carbidopa in subjects with fibromyalgia (FMS201). Ongoing study. January 2009. Contact author for more information.">NCT01323374</a>; <a href="./references#CD010585-bbs2-0056" title="A study of IMC-1 in patients with fibromyalgia. Ongoing study. May 2013. Contact author for more information.">NCT01850420</a>). No results for any of these studies were available at the time of this review. Study details are provided in the <a href="./references#CD010585-sec-0187" title="">Characteristics of ongoing studies</a> table. </p> </section> <section id="CD010585-sec-0043"> <h4 class="title">Included studies</h4> <section id="CD010585-sec-0044"> <h5 class="title">Study selection</h5> <p>Sixteen studies met our criteria for inclusion in this systematic review.</p> <p> <ul id="CD010585-list-0006"> <li> <p>Three studies (306 participants randomised) involved a combination of an NSAID with a benzodiazepine (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). </p> </li> <li> <p>Two studies (89 participants randomised) evaluated amitriptyline combined with fluoxetine (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> </li> <li> <p>Two studies (92 participants randomised) compared amitriptyline with a drug from a different class of medication (naproxen: <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; lidocaine: <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). </p> </li> <li> <p>Two studies (164 participants randomised) evaluated the effects of melatonin combined with an antidepressant (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>). </p> </li> <li> <p>One study (58 participants randomised) evaluated the combination of carisoprodol, paracetamol (acetaminophen), and caffeine (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). </p> </li> <li> <p>One study (315 participants randomised) assessed the combination of tramadol with paracetamol (acetaminophen) (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>). </p> </li> <li> <p>One study (24 participants randomised) combined malic acid with magnesium (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>). </p> </li> <li> <p>One study (200 participants randomised) combined a monoamine oxidase inhibitor (MAOI) with 5‐hydroxytryptophan (5‐HTP) (<a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). </p> </li> <li> <p>One study (41 participants randomised) combined pregabalin with duloxetine (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>). </p> </li> </ul> </p> <p>Most studies (nine) diagnosed fibromyalgia using the 1990 (<a href="./references#CD010585-bbs2-0121" title="WolfeF , SmytheHA , YunusMB , BennettRM , BombardierC , GoldenbergDL , TugwellP , CampbellSM , AbelesM , ClarkP , et al. The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee.. Arthritis Rheum. 1990 Feb;33(2):160-72.">Wolfe 1990</a>) American College of Rheumatology (ACR) guidelines (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). One study used the updated 2010 (<a href="./references#CD010585-bbs2-0124" title="WolfeF , ClauwDJ , FitzcharlesMA , GoldenbergDL , KatzRS , MeaseP , RussellAS , RussellIJ , WinfieldJB , Yunus MB. The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity.. Arthritis Care Res 2010 May;62(5):600-10.">Wolfe 2010</a>) ACR classification guidelines (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>). Two studies used older criteria for diagnosing fibromyalgia from <a href="./references#CD010585-bbs2-0126" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a> (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>). Participants in one study met the criteria outlined in both <a href="./references#CD010585-bbs2-0126" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a> and <a href="./references#CD010585-bbs2-0114" title="SmytheHA . Fibrositis as a disorder of pain modulation. Clinics in Rheumatic Diseases1979;5(3):823-32.">Smythe 1979</a> (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). One study reported the proportion of their study population who met the 1990 ACR fibromyalgia diagnostic criteria (&gt; 87%), and criteria outlined in <a href="./references#CD010585-bbs2-0126" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a> (&gt; 97%), <a href="./references#CD010585-bbs2-0120" title="WolfeF , HawleyDJ , CatheyMA , CaroXJ , RussellIJ . Fibrositis: symptom frequency and criteria for diagnosis. An evaluation of 291 rheumatic disease patients and 58 normal individuals. Journal of Rheumatology1985;12(6):1159-63.">Wolfe 1985</a> (&gt; 97%), <a href="./references#CD010585-bbs2-0113" title="SmytheHA , MoldofskyH . Two contributions to understanding the “fibrositis syndrome”. Bulletin on the Rheumatic Diseases1977;28(1):928-31.">Smythe 1977</a> (88%), and <a href="./references#CD010585-bbs2-0061" title="CampbellSM , ClarkS , TindallEA , ForehandME , BennettRM . Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points. Arthritis and Rheumatism1983;26(7):817-24.">Campbell 1983</a> (88%) (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). </p> <p>See <a href="./references#CD010585-sec-0185" title="">Characteristics of included studies</a> table for full characteristics of all included studies. </p> </section> <section id="CD010585-sec-0045"> <h5 class="title">Study design</h5> <p>See <a href="#CD010585-tbl-0002">Table 1</a> for information on study methodology. There are 16 included studies, with a total of 1474 participants randomised. </p> <div class="table" id="CD010585-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methodology of included trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>First author, year</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Trial comparisons</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo‐controlled</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. only 1 component</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. both components</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. other</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0001" title="Albertoni GiraldesAL , SalomãoR , LealPD , BrunialtiMK , SakataRK . Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: a randomized double-blind study. International Journal of Rheumatic Diseases2016;19(10):946-53. ">Albertoni Giraldes 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0010" title="PridgenWL , DuffyC , GendreauJF , GendreauRM . A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. Journal of Pain Research2017;10:451-60. ">Pridgen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a> compared a monoamine oxidase inhibitor, 5‐hydroxytryptophan, their combination, and amitriptyline. </p> </div> </div> <p>Ten of the 16 included studies used a parallel study design (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). Three studies used a cross‐over design (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>). The remaining study was designed as a series of individual N‐of‐1 trials (i.e. involving multicross‐over combinations) (<a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Two studies included an open‐label component after a double‐blind phase (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>). </p> <p>One study assessed the combination of three different agents (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>), while the remaining 13 studies assessed the combination of two drugs (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Nine studies involved the comparison of the combination with each drug alone (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). Six of these nine studies also included a placebo‐only comparator group (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>), and one of these nine studies also had a treatment arm that received a different single drug that was not part of the combination arm (<a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). Three studies compared a combination of drugs to a placebo only (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). Two studies compared the combination of two drugs to only one of the drugs alone (<a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). All but one study used medications in tablet or capsule form, taken orally; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> administered one agent orally and one agent intravenously. </p> </section> <section id="CD010585-sec-0046"> <h5 class="title">Permitted concomitant analgesic medications</h5> <p>One study did not specify whether concomitant medications were permitted during the trial (<a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). </p> <p>Three studies did not permit the use of concomitant analgesic medications (<a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a> excluded participants if they were taking analgesics, anti‐inflammatories, or antioxidants such as aspirin. While <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> did not provide details on concomitant medications, in a subsequent overlapping publication containing some of the same data, the authors describe the exclusion of participants if they had used any analgesics with a central nervous system action such as antidepressants, anticonvulsants, opioids, or neuroleptics within four weeks of study enrolment (<a href="./references#CD010585-bbs2-0051" title="VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2011</a>). However, neither <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> nor <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a> explicitly stated that additional medications were not permitted during the trial. <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a> required participants to discontinue psychotropic drugs, analgesics, and NSAIDs for at least three weeks before study enrolment, and excluded participants from efficacy analyses if they took any of these prohibited medications during the trial. Participants were permitted to take paracetamol (acetaminophen) during the wash‐out period only. </p> <p><a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a> permitted paracetamol (acetaminophen) during a two‐week washout period before the study start. Four studies permitted the use of paracetamol (acetaminophen) only (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Most participants in <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a> and <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a> did not take paracetamol (acetaminophen) during the trial; the number of participants taking paracetamol (acetaminophen) is not reported in <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a> or <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>. One study permitted participants to take any medication needed, and compared the use of additional drugs (defined as at least one tablet daily for three consecutive days) between treatment groups (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). Ten of 23 participants in the placebo group and none of 20 participants in the combination group used tricyclic antidepressants, anxiolytics, or sedatives, while 13 of 23 participants in the placebo group and four of 20 participants in the combination group used analgesics for pain relief; the most frequently used medication was paracetamol (acetaminophen). </p> <p><a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a> permitted the use of either a low‐dose selective serotonin reuptake inhibitors (SSRI) or St. John’s wort, and also allowed the use of one of the sedatives zolpidem or flurazepam; however, use was restricted to participants who had been on steady doses for at least one month prior to study enrolment. Thirty of 156 participants in the combination group and 26 of 157 participants in the placebo group took an SSRI for depression; the primary outcome result did not change when these participants were included or excluded in analyses. Two studies permitted the use of NSAIDs, paracetamol (acetaminophen), or opioids (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>). <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a> permitted participants to remain on analgesic medications provided these drugs were not adjusted during the study. Additionally, all participants could use paracetamol (acetaminophen), ibuprofen, Dorflex® (35 mg orfenadrine citrate, 300 mg dipyrone, 50 mg caffeine), codeine, or tramadol. Within three months of study enrolment, 50 of 63 participants had used paracetamol (acetaminophen)/dipyrone, 26 of 63 had used an NSAID, and 1 of 63 had used an opioid regularly. During the study, 42 of 63 participants were taking an antidepressant, five of 63 were taking an anticonvulsant, and seven of 63 were taking a benzodiazepine. Treatment groups did not differ significantly in their use of analgesics. <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a> permitted participants to use NSAIDs, paracetamol (acetaminophen), and/or opioids at a stable dose throughout the trial. Ten of 24 participants took paracetamol (acetaminophen), 11 of 41 participants took NSAIDs, 1 of 41 took codeine, 2 of 41 took baclofen, 2 of 41 took methocarbamol, and 1 of 41 took glucosamine. </p> </section> <section id="CD010585-sec-0047"> <h5 class="title">Study outcomes</h5> <p>Seven studies did not specify a primary outcome versus a secondary outcome (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). </p> <p> <ul id="CD010585-list-0007"> <li> <p>All 16 studies reported pain scores, 12 of which used visual analogue scales (VAS) (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), and two of which used numerical rating scales (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>) for pain. Most studies also reported other indices of pain or discomfort, including the number of tender points or tender points index (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), duration or presence/absence of morning stiffness (<a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>), myalgic score (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>), pressure pain threshold at various tender points (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>), pain relief (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>), pain reduction during the conditioned pain modulation task (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>), and VAS scores for general feeling of sickness (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). One study reported the cumulative time to discontinuation from study participation (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>). </p> </li> <li> <p>Nine studies included an assessment of sleep quality (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), and one study measured fatigue and sleep disorders as present/absent at baseline versus after treatment (<a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). </p> </li> <li> <p>One study assessed physical activity (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>). </p> </li> <li> <p>Nine studies included several other secondary outcomes including the Fibromyalgia Impact Questionnaire (FIQ) (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), the Brief Pain Inventory (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>), the Short Form McGill Pain Questionnaire (SF‐MPQ) (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>), the Beck Depression Inventory (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>), the Center for Epidemiologic Studies Depression Scale (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>), the Hamilton Depression Scale (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>), the Hamilton Anxiety Rating Scale (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>), the Beck Anxiety Inventory (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>), the Health Assessment Questionnaire (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>), the Short‐Form (36) Health Survey (SF‐36) (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>), the Hassles Scale (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>), and the Medical Outcomes Study Sleep Scale (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>). </p> </li> <li> <p>Eight studies recorded the number of adverse events/side effects (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> </li> <li> <p>One study assessed the presence/absence of subjective edema, paresthesia, and headache before and after treatment (<a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>) </p> </li> <li> <p>Three studies reported the number of participants taking various concomitant analgesics in addition to study drugs during the trial (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). </p> </li> <li> <p>Six studies included a global assessment or improvement score, or both (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> </li> <li> <p>Finally, one study quantified blood levels of brain‐derived neurotrophic factor (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>). </p> </li> </ul> </p> </section> </section> <section id="CD010585-sec-0048"> <h4 class="title">Excluded studies</h4> <p>We excluded 37 studies. A justification for each full‐text study that we excluded can be seen in the <a href="./references#CD010585-sec-0186" title="">Characteristics of excluded studies</a> table. Briefly, we excluded all single‐blind (<a href="./references#CD010585-bbs2-0044" title="QinL , JiangF , et al. Effect of treating fibromyalgia syndrome with the combination of tramadol and amitriptyline. Chinese Journal of Rural Medicine and Pharmacy2009;8:18-19. ">Qin 2009</a>), add‐on (<a href="./references#CD010585-bbs2-0025" title="CuatrecasasG , RiudavetsC , GüellMA , NadalA . Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskeletal Disorders2007;8(119):1-9. ">Cuatrecasas 2007</a>; <a href="./references#CD010585-bbs2-0026" title="CuatrecasasCA , GonzalezMJ , Fernandez-SolaJ , Garcia-FructuosoF , SesmiloF , LageM , et al. Effect of growth hormone as add-on treatment in severe fibromyalgia syndrome. Results from the IIIB, CT27560 placebo-controlled, multicenter trial. Annals of the Rheumatic Diseases2011;70(Suppl 3):562. ">Cuatrecasas 2011</a>; <a href="./references#CD010585-bbs2-0027" title="CuatrecasasG , AlegreC , Fernandez-SolàJ , GonzalezMJ , Garcia-FructuosoF , Poca-DiasV , et al. Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia. Pain2012;153(7):1382-9. ">Cuatrecasas 2012</a>; <a href="./references#CD010585-bbs2-0028" title="FarmerM , DayaniN , TrugmanJ , WangY , GendreauR . Effect of adding milnacipran to pregabalin in the management of fibromyalgia: a randomized, open-label, controlled study. Journal of Pain2010;11(4):S17. ">Farmer 2010</a>; <a href="./references#CD010585-bbs2-0031" title="HolmanAJ , MyersRR . A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis and Rheumatism2005;52(8):2495-505. ">Holman 2005</a>; <a href="./references#CD010585-bbs2-0035" title="LeaderA , AmitalD , RubinowA , AmitalH . An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome. Annals of the New York Academy of Sciences2009;1173(1):829-36. ">Leader 2009</a>; <a href="./references#CD010585-bbs2-0042" title="PotvinS , MorinM , CloutierC , GendronA , BissonnetteA , MarchandS . Add-on treatment of quetiapine for fibromyalgia: a pilot, randomized, double-blind, placebo-controlled 12-week trial. Journal of Clinical Psychopharmacology2012;32(5):684-7. ">Potvin 2012</a>; <a href="./references#CD010585-bbs2-0047" title="Rico-VillademorosF , HidalgoJ , Morillas-ArquesP , VilchezJS , Delgado-RodriguezA , CalandreEP . An open-label study of levopromazine (methotrimeprazine) as an add-on therapy in fibromyalgia management. Clinical and Experimental Rheumatology2009;27(5):S16-20. ">Rico‐Villademoros 2009</a>; <a href="./references#CD010585-bbs2-0050" title="VilchezJS , CalandreEP , Rico-VillademorosF , Molina-BareaR , Rodriguez-LopezCM , Garcia-CarrilloJ . Ropinirole as a coadjuvant treatment in the management of refractory patients with fibromyalgia: a case series. European Neuropsychopharmacology2009;19(Suppl 3):S270. ">Vilchez 2009</a>), non‐randomised (<a href="./references#CD010585-bbs2-0052" title="ZborovskyAB , BabyevaAR , GrekhovRA . The combination of the local therapy with dimethylsulfoxide and NSAIDs and acupuncture in the treatment of patients with fibromyalgia. Zeitschrift für Rheumatologie1994;53(2):112. ">Zborovsky 1994</a>), and open‐label studies (<a href="./references#CD010585-bbs2-0018" title="BagisS , KarabiberM , AsI , TamerL , ErdoganC , AtalayA . Is magnesium citrate treatment effective on pain, clinical parameters and functional status in patients with fibromyalgia?Rheumatology International2013;33(1):167-72. ">Bagis 2013</a>; <a href="./references#CD010585-bbs2-0020" title="CalandreEP , Morillas-ArquesP , Rodriguez-LopezCM , Rico-VillademorosF , HidalgoJ . Pregabalin augmentation of quetiapine therapy in the treatment of fibromyalgia: an open-label, prospective trial. Pharmacopsychiatry2007;40(2):68-71. ">Calandre 2007</a>; <a href="./references#CD010585-bbs2-0021" title="CalandreEP , Morillas-ArquesP , Molina-BareaR , Rodriguez-LopezCM , Rico-VillademorosF . Trazodone plus pregabalin combination in the treatment of fibromyalgia: a two-phase, 24-week, open-label uncontrolled study. BMC Musculoskeletal Disorders2011;12(95):1-9. ">Calandre 2011</a>; <a href="./references#CD010585-bbs2-0022" title="CantiniF , BellandiF , NiccoliL , Di MunnoO . Fluoxetine associated with cyclobenzaprine to treat fibromyalgia [Fluoxetina associate a ciclobenzaprina nel trattamento della fibromyalgia]. Minerva Medica1994;85(3):97-100. ">Cantini 1994</a>; <a href="./references#CD010585-bbs2-0023" title="CantiniF , NiccoliL , BellandiF , Di MunnoO . Effectiveness of fluoxetine associated with cyclobenzaprine in the treatment of fibromyalgia: twelve-months-follow up results. Reumatismo1995;85:103-8. ">Cantini 1995</a>; <a href="./references#CD010585-bbs2-0025" title="CuatrecasasG , RiudavetsC , GüellMA , NadalA . Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskeletal Disorders2007;8(119):1-9. ">Cuatrecasas 2007</a>; <a href="./references#CD010585-bbs2-0028" title="FarmerM , DayaniN , TrugmanJ , WangY , GendreauR . Effect of adding milnacipran to pregabalin in the management of fibromyalgia: a randomized, open-label, controlled study. Journal of Pain2010;11(4):S17. ">Farmer 2010</a>; <a href="./references#CD010585-bbs2-0029" title="FossaluzzaV , De VitaS . Combined therapy with cyclobenzaprine and ibuprofen in primary fibromyalgia syndrome. International Journal of Clinical Pharmacology Research1992;12(2):99-102. ">Fossaluzza 1992</a>; <a href="./references#CD010585-bbs2-0035" title="LeaderA , AmitalD , RubinowA , AmitalH . An open-label study adding creatine monohydrate to ongoing medical regimens in patients with the fibromyalgia syndrome. Annals of the New York Academy of Sciences2009;1173(1):829-36. ">Leader 2009</a>; <a href="./references#CD010585-bbs2-0037" title="ListerRE . An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. Journal of International Medical Research2002;30(2):195-9. ">Lister 2002</a>; <a href="./references#CD010585-bbs2-0038" title="MeasePJ , FarmerMV , PalmerRH , GendreauRM , TrugmanJM , WangY . Milnacipran combined with pregabalin in fibromyalgia: a randomized, open-label study evaluating the safety and efficacy of adding milnacipran in patients with incomplete response to pregabalin. Therapeutic Advances in Musculoskeletal Disease2013;5(3):113-26. ">Mease 2013</a>; <a href="./references#CD010585-bbs2-0045" title="RamzyEA . Comparative efficacy of newer antidepressants in combination with pregabalin for fibromyalgia syndrome: a controlled, randomized study. Pain Practice2017;17(1):32-40. ">Ramzy 2017</a>; <a href="./references#CD010585-bbs2-0047" title="Rico-VillademorosF , HidalgoJ , Morillas-ArquesP , VilchezJS , Delgado-RodriguezA , CalandreEP . An open-label study of levopromazine (methotrimeprazine) as an add-on therapy in fibromyalgia management. Clinical and Experimental Rheumatology2009;27(5):S16-20. ">Rico‐Villademoros 2009</a>; <a href="./references#CD010585-bbs2-0048" title="SettelE . Efficacy of phenylbutazone-prednisone combination in the treatment of acute lumbosacral fibrositis: a survey of 96 cases. Current Therapeutic Research, Clinical and Experimental1967;9(4):197-9. ">Settel 1967</a>; <a href="./references#CD010585-bbs2-0050" title="VilchezJS , CalandreEP , Rico-VillademorosF , Molina-BareaR , Rodriguez-LopezCM , Garcia-CarrilloJ . Ropinirole as a coadjuvant treatment in the management of refractory patients with fibromyalgia: a case series. European Neuropsychopharmacology2009;19(Suppl 3):S270. ">Vilchez 2009</a>), as well as all studies involving a non‐drug therapy such as acupuncture, Chinese herbal medicine, botulinum toxin, and vitamins or other micronutrients (<a href="./references#CD010585-bbs2-0017" title="AliA , NjikeVY , NorthrupV , SabinaAB , WilliamsAL , LibertiLS , et al. Intravenous micronutrient therapy (Myers’ Cocktail) for fibromyalgia: a placebo-controlled pilot study. Journal of Alternative and Complementary Medicine2009;15(3):247-57. ">Ali 2009</a>; <a href="./references#CD010585-bbs2-0032" title="JacobsJWG , RaskerJJ , Van RielPLCM , GribnauFWJ . Rheumajecta and Vasolastine treatment of primary fibromyalgia: results of a randomized, placebo-controlled, double-blind study [Behandeling met Rheumajecta en Vasolastine van primaire fibromyalgie; resultaten van een gerandomiseerd, placebo-gecontroleerd, dubbelblind onderzoek]. Nederlands Tijdschrift voor Geneeskunde1990;134(14):693-7. ">Jacobs 1990</a>; <a href="./references#CD010585-bbs2-0034" title="LangeM , Krohn-GrimbergheB , PetermannF . Medium-term effects of a multimodal therapy on patients with fibromyalgia. Results of a controlled efficacy study [Mittelfristige effekte einer multimodalen behandlung bei patienten mit fibromyalgiesyndromergebnisse einer kontrollierten wirksamkeitsstudie]. Der Schmerz2011;25(1):55-61. ">Lange 2011</a>; <a href="./references#CD010585-bbs2-0037" title="ListerRE . An open, pilot study to evaluate the potential benefits of coenzyme Q10 combined with Ginkgo biloba extract in fibromyalgia syndrome. Journal of International Medical Research2002;30(2):195-9. ">Lister 2002</a>; <a href="./references#CD010585-bbs2-0040" title="PortaM . The use of botulinum toxin type A in the treatment of myofascial pain syndromes. Riabilitazione1999;32(2):49-55. ">Porta 1999</a>; <a href="./references#CD010585-bbs2-0041" title="PortaM . A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain2000;85(1-2):101-5. ">Porta 2000</a>; <a href="./references#CD010585-bbs2-0053" title="ZhaoRH , ZhuYB . Observation on therapeutic effect of herb-partitioned moxibustion on fibromyalgia syndrome. Zhonqquo Zhen Jiu2009;29(3):200-2. ">Zhao 2009</a>), studies whose populations did not consist solely of those with fibromyalgia (<a href="./references#CD010585-bbs2-0024" title="ChoiJW , LeeCJ , LeeSM , ShinBS , JunB , SimWS . Effect of hyaluronidase addition to lidocaine for trigger point injection in myofascial pain syndrome. Pain Practice 2015 Oct 7 [Epub ahead of print]. [DOI: 10.1111/papr.12362]">Choi 2015</a>; <a href="./references#CD010585-bbs2-0036" title="Le GallezP , ReeveFB , CrawleyMA , BirdHA . A double-blind comparison of ibuprofen, placebo and ibuprofen with meptazinol in soft tissue rheumatism. Current Medical Research and Opinon1988;10(10):663-7. ">Le Gallez 1988</a>; <a href="./references#CD010585-bbs2-0040" title="PortaM . The use of botulinum toxin type A in the treatment of myofascial pain syndromes. Riabilitazione1999;32(2):49-55. ">Porta 1999</a>; <a href="./references#CD010585-bbs2-0041" title="PortaM . A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain2000;85(1-2):101-5. ">Porta 2000</a>; <a href="./references#CD010585-bbs2-0049" title="SzirmaiE , SachsV . Experimental investigation of the effect of a combination of quinine, lithium and salicylic acid by means of various methods [Experimentelle prüfung der wirkung einer chinin-lithium-salicylat-kombination mit verschiedenen methoden]. Arzneimittelforschung1974;24(9):1322-5. ">Szirmai 1974</a>). The <a href="./references#CD010585-sec-0186" title="">Characteristics of excluded studies</a> table gives reasons for exclusions. </p> <p>We identified two secondary publications of data in included studies (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0051" title="VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2011</a>). </p> </section> </section> <section id="CD010585-sec-0049"> <h3 class="title">Risk of bias in included studies</h3> <p>Two review authors (JBT and IG) independently evaluated each study using the Cochrane 'Risk of bias' tool (<a href="./references#CD010585-bbs2-0083" title="HigginsJPT , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomized trials. BMJ2011;343(d5928):1-9.">Higgins 2011b</a>). The risk ratings for each source of potential bias in included studies are shown in <a href="#CD010585-fig-0002">Figure 2</a>, and the percentage of studies falling into each risk rating category (low, unclear, and high) for each source of potential bias is shown in <a href="#CD010585-fig-0003">Figure 3</a>. Details and justification for each rating are included in the <a href="./references#CD010585-sec-0185" title="">Characteristics of included studies</a> table. </p> <div class="figure" id="CD010585-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010585-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <div class="figure" id="CD010585-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010585-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> </div> <section id="CD010585-sec-0050"> <h4 class="title">Allocation</h4> <p>Only five studies reported randomisation methods (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), and only five studies reported the method of allocation concealment (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> </section> <section id="CD010585-sec-0051"> <h4 class="title">Blinding</h4> <p>Only seven studies gave appropriate detail on how participants and personnel were blinded (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). We classified seven studies as having an unclear risk of bias for participant and personnel blinding (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> <p>Eight studies did not describe in appropriate detail how outcome assessment was protected from bias by blinding (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). We rated six studies as having low detection bias (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). </p> </section> <section id="CD010585-sec-0052"> <h4 class="title">Incomplete outcome data</h4> <p>We judged six studies to have an unclear risk of bias for incomplete outcome data (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). Of these studies, two did not mention whether or not there was any attrition of study participants (<a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). The remaining studies did describe the number of withdrawals with varying levels of detail; however, questions remained due to lack of reporting of the final sample size (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>), sample sizes that appeared inconsistent with the number of reported study withdrawals (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>), and lack of detail about which treatment participants were on when they withdrew from the trial (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). Seven studies had a low risk for attrition bias (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), while we rated one study as having a high risk for attrition bias due to uneven withdrawal rates between treatment groups (<a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>). </p> </section> <section id="CD010585-sec-0053"> <h4 class="title">Selective reporting</h4> <p>Eleven studies did not have registered protocols (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Eight of these studies had an unclear risk of bias for this reason (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>) or because of a lack of information to allow for a determination (<a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>). Three studies had registered protocols (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). The protocols did not differ in significant ways from the published reports of two of these studies, and we therefore rated them as having a low risk of bias (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>). Four studies had a high risk of bias for selective reporting, due to one or more of the following: inappropriate statistical analyses, data interpretation not supported by the statistical analyses performed, lack of detail about outcome measures in the methods section, and outcome measures discussed in the methods section for which no data were shown (<a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). </p> </section> <section id="CD010585-sec-0054"> <h4 class="title">Size of study</h4> <p>We assessed all included studies for risk of bias in terms of sample size. Most studies had very small sample sizes, with fewer than 50 participants per arm (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>) and we therefore classified them as having a high risk of bias. Two studies had 50 to 199 participants per arm and we therefore classified them as unclear risk (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). </p> </section> <section id="CD010585-sec-0055"> <h4 class="title">Trial duration</h4> <p>We assessed all included studies for risk of bias in terms of trial length (<a href="./references#CD010585-bbs2-0095" title='MooreRA , EcclestonC , DerryS , WiffenP , BellRF , StraubeS , et al, ACTINPAIN Writing Group of the IASP Special Interest Group on Systematic Reviews in Pain Relief, Cochrane Pain Palliative and Supportive Care Systematic Review Group Editors. "Evidence" in chronic pain - establishing best practice in reporting of systematic reviews. Pain2010;150(3):369-89.'>Moore 2010b</a>). No trials were shorter than four weeks in duration. Nine studies had treatment period durations of three to six weeks, falling into the unclear risk category (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). We classified five studies as low risk in terms of trial duration, with treatment periods of at least seven weeks (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). </p> </section> <section id="CD010585-sec-0056"> <h4 class="title">Similarities of baseline</h4> <p>We also assessed all included studies for risk of bias with respect to similarities in age, sex ratio, and pain scores at baseline between groups. Seven studies had a low risk of bias for similarities of baseline characteristics, with age, sex ratio, and pain scores at baseline being statistically similar between groups (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Six studies had an unclear risk of bias for similarities of baseline characteristics because comparisons were not made between treatment groups for age, sex ratio, and/or pain scores (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). One study had a high risk of bias for similarities of baseline characteristics because one treatment group had significantly higher baseline pain scores than the other treatment groups (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>). </p> </section> </section> <section id="CD010585-sec-0057"> <h3 class="title" id="CD010585-sec-0057">Effects of interventions</h3> <p>See: <a href="./full#CD010585-tbl-0001"><b>Summary of findings 1</b> Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</a> </p> <p>None of the combinations of drugs found provided sufficient data for analysis compared with placebo or other comparators for our preferred outcomes. We therefore provide a narrative description of results. </p> <p>Our GRADE assessment for all outcomes found very low‐quality evidence. At a minimum, there were few or no results for analysis, and there were frequently other risk of bias issues in addition (<a href="./full#CD010585-tbl-0001">summary of findings Table 1</a>). </p> <section id="CD010585-sec-0058"> <h4 class="title">NSAIDs combined with benzodiazepines</h4> <p>Three trials combined an NSAID with a benzodiazepine (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). </p> <p><a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a> compared the combination of alprazolam and ibuprofen to each drug on its own and to a double placebo in a four‐group, parallel‐design, five‐week study. The study randomised 64 participants and conducted analyses on the 61 participants who completed at least one week on treatment (the evaluable cohort), and on the 45 participants who completed all five weeks on the study drug. </p> <p><a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a> also evaluated the effects of alprazolam and ibuprofen, alone and in combination, along with a double‐placebo treatment in a six‐week, four‐group, parallel‐design study. The study randomised 78 participants; they included 76 in the safety analysis, and the 63 participants who completed the trial were included in the efficacy analysis. </p> <p><a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a> compared the effects of tenoxicam and bromazepam alone and in combination in a four‐group, placebo‐controlled, parallel‐design, eight‐week trial. The study randomised 164 participants and analyzed them on an ITT basis; 134 participants completed at least three weeks of treatment and were also analyzed separately. </p> <section id="CD010585-sec-0059"> <h5 class="title">Kravitz 1994</h5> <section id="CD010585-sec-0060"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0061"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0062"> <h6 class="title">Patient‐reported global impression of clinical change much or very much improved</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0063"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0064"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest that were reported on in this study were VAS pain scores, VAS pain relief scores, number of tender points, global improvement from baseline, withdrawals due to lack of efficacy, participants experiencing any adverse event, withdrawals due to adverse events and specific adverse events, particularly somnolence and dizziness. Serious adverse events were not reported. </p> <p>When comparing VAS pain scores of the 45 study completers between groups for each week in the trial, there were no significant differences. In the evaluable cohort, VAS pain relief scores were significantly different in weeks four and five, with the alprazolam group having significantly higher relief scores compared to the double placebo at both weeks, and compared to the combination group at week four. </p> <p>Only at week four was there a statistically significant difference in the number of tender points, with the ibuprofen‐ and alprazolam‐alone groups having significantly fewer tender points than the combination and placebo groups. </p> <p>No statistically significant differences were seen in either clinician‐rated or self‐rated global improvement scores at any week during the study. However, only those participants who completed all five weeks of the study had clinical global improvement scores indicating much or very much improved (score of 1 or 2). </p> <p>While not statistically significant, clinicians rated more participants in the ibuprofen and alprazolam groups (70% and 58%, respectively) as being much or very much improved by the end of the trial, compared to the combination and double‐placebo groups (40% and 30%, respectively). </p> <p>Eleven participants withdrew from the study due to a lack of efficacy of treatment; their group allocations were not disclosed. </p> <p>Adverse events were as expected, with sedation, drowsiness, fatigue, and weakness being more common in all participants receiving alprazolam. Participants in all groups experienced headache and gastrointestinal (GI) symptoms. Headache was more severe in the alprazolam group, and GI symptoms were more severe in all participants receiving ibuprofen. </p> <p>Two participants withdrew from the study due to adverse events, and both had been randomised to the combination therapy group. </p> </section> </section> <section id="CD010585-sec-0065"> <h5 class="title">Russell 1991</h5> <section id="CD010585-sec-0066"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0067"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0068"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0069"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>No results were reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0070"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Some secondary outcomes of interest were recorded in this study, including severity of tenderness, tender point index, VAS pain scores, physician’s global perception of overall disease severity, and withdrawals due to adverse events. </p> <p>Within‐group comparisons indicated statistically significant improvement in dolorimeter scores, tender point index, pain scores, and physician‐rated global assessment scores between baseline and week six of treatment; however, there was no statistically significant difference in the change from baseline between treatment groups. </p> <p>Comparing the combination group to the double‐placebo group suggested that the combination treatment significantly decreased pain and tender point index, but not dolorimeter score or physician‐rated global assessment. </p> <p>The number of participants reporting adverse events was not provided. However, only six participants withdrew from the study due to adverse events, four of whom were in the placebo group and experienced blurred vision, GI problems, headaches, emesis, and nasal congestion. Only one participant in the combination group withdrew due to adverse events, reporting rash, adenopathy, headaches, swelling, and increased pain. </p> </section> </section> <section id="CD010585-sec-0071"> <h5 class="title">Quijada‐Carrera 1996</h5> <section id="CD010585-sec-0072"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0073"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0074"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0075"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0076"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>This study reported outcomes related to pain including participant global assessment of fibromyalgia, VAS pain scores, duration of morning stiffness, and number of tender points; it also reported withdrawals due to adverse events. </p> <p>In the analysis of participants who completed at least three weeks of treatment, there was no statistically significant effect of treatment on participant‐rated global assessment. In the ITT analysis, significantly more participants in the combination group (29%) had clinically significant improvement scores compared to the tenoxicam‐only group (10%). </p> <p>The proportion of participants experiencing clinically significant improvement from baseline in pain (defined as a decrease of at least 25%), sleep quality (defined as more rested upon awakening), and duration of morning stiffness (defined as at least a 25% decrease) did not differ statistically between treatment groups. </p> <p>The proportion of participants with a reduction of at least four tender points compared to baseline was significantly higher in the combination group compared to the bromazepam group, but no other groups. </p> <p>No average scores were reported in this study; rather, the proportion of participants experiencing improvement from baseline in each outcome was reported. </p> <p>Nine participants withdrew from the study due to adverse events; 52 participants overall reported experiencing adverse events (7, 18, 14, and 13 in the placebo, tenoxicam, bromazepam, and combination groups, respectively). </p> <p>The most common side effects reported were gastralgia (tenoxicam, bromazepam, and combination groups), nausea (placebo and tenoxicam groups), headache (tenoxicam group), and drowsiness (bromazepam group). </p> <p>The study authors concluded that combination therapy was not significantly better than placebo, likely due to low power in the study, and a higher than expected response to placebo treatment. </p> </section> </section> </section> <section id="CD010585-sec-0077"> <h4 class="title">Amitriptyline combined with fluoxetine</h4> <p>Two studies evaluated the efficacy of amitriptyline and fluoxetine alone and in combination (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). </p> <p><a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>, a cross‐over design trial, gave amitriptyline, fluoxetine, combination therapy, and placebo to participants sequentially for six‐week durations each. The study randomised 31 participants, and included 24 participants, who completed at least one treatment period, in the analyses. </p> <p><a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a> also evaluated the combination of fluoxetine and amitriptyline in the treatment of fibromyalgia, but only compared this combination to amitriptyline monotherapy using an N‐of‐1 trial design in which participants received three sequential, six‐week, cross‐over trials involving a defined sequence of amitriptyline‐combination pairs. The study enrolled 58 participants. Thirty‐four participants completed all treatment periods and 46 participants completed at least two treatment periods; both subsets of participants were analyzed. </p> <section id="CD010585-sec-0078"> <h5 class="title">Goldenberg 1996</h5> <section id="CD010585-sec-0079"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0080"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0081"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0082"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0083"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest related to pain were: FIQ scores, VAS pain scores, VAS global well‐being scores, and tender point scores; withdrawals due to adverse events were also reported. </p> <p>Compared to the placebo treatment outcomes, amitriptyline and fluoxetine monotherapy significantly improved self‐reported VAS scores of pain, sleep, and global well‐being, and also improved FIQ scores. </p> <p>Combination therapy resulted in significantly larger improvements in these four outcomes compared to each monotherapy. </p> <p>No statistically significant differences between treatment groups were seen in the VAS scores for physician‐rated global well‐being, fatigue, or feeling refreshed. </p> <p>Similarly, there was no statistically significant influence of treatment on the Beck Depression Inventory score and on the tender point score, although the study authors noted that the combination therapy was associated with the greatest improvements in these measures. </p> <p>Analyses on the change from baseline to week six of treatment produced similar trends, with the combination treatment resulting in the largest improvement and the placebo treatment the smallest (significance not specified). </p> <p>A greater than 25% improvement to FIQ scores was seen in 12/19 participants on combination therapy, 7/22 receiving fluoxetine, 5/21 receiving amitriptyline, and 1/19 receiving placebo (significance not specified). </p> <p>When all four outcomes (VAS for global well‐being, pain, and physician‐rated global well‐being, and tender point score) were combined into a composite change score out of 100, an improvement by at least 25 points was seen in five participants taking combination therapy, five receiving fluoxetine, two receiving amitriptyline, and one receiving placebo (significance not specified). </p> <p>Nine of 12 participants who withdrew from the study cited either adverse reactions to the medication (one fluoxetine, three combination, one placebo) or worsening fibromyalgia symptoms (three fluoxetine, one during a washout period) as the reason. </p> <p>The study authors concluded that the combination of amitriptyline and fluoxetine was more effective than placebo and either monotherapy in improving FIQ scores, and in participant‐rated VAS scores of global well‐being, pain, and sleep. </p> </section> </section> <section id="CD010585-sec-0084"> <h5 class="title">Zucker 2006</h5> <section id="CD010585-sec-0085"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0086"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0087"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0088"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0089"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest related to pain included FIQ scores, VAS scores of global well‐being and pain, and tender point scores. Withdrawals due to adverse events were also reported. </p> <p>Participants receiving combination therapy had significantly improved FIQ scores, VAS pain scores, and tender point exam scores compared to those receiving amitriptyline alone. </p> <p>There were no statistically significant differences between treatments in other outcome measures (VAS scores of global well‐being, sleep, fatigue, and feeling refreshed upon awakening). </p> <p>Eight participants withdrew due to adverse events, the most frequently reported of which were sedation, headache, "dryness", and GI‐related symptoms. Seven out of eight participants were taking combination therapy when they withdrew, and one was taking amitriptyline. </p> <p>The study authors concluded that combination therapy, in comparison to amitriptyline monotherapy, improved FIQ scores. </p> </section> </section> </section> <section id="CD010585-sec-0090"> <h4 class="title">Amitriptyline combined with a drug from another class of medication</h4> <p>Two studies combined amitriptyline with another agent (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). </p> <p><a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a> compared the combination of amitriptyline and naproxen to each monotherapy and to double placebo in a six‐week, four‐group, parallel‐design trial. The study randomised 62 participants, and included the 58 participants who completed the study in the analysis. They evaluated participants at baseline, and at two, four, and six weeks after starting treatment. </p> <p><a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> compared amitriptyline monotherapy to combination therapy of amitriptyline and intravenous lidocaine in a four‐week, two‐group, parallel‐design study. The study randomised and analyzed 30 participants. </p> <section id="CD010585-sec-0091"> <h5 class="title">Goldenberg 1986</h5> <section id="CD010585-sec-0092"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0093"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0094"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0095"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0096"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest related to pain were recorded in this study, and included VAS scores of global assessment of fibromyalgia symptoms and pain, in addition to tender point scores. Adverse events were also reported. </p> <p>The study authors ran a profile analysis, which evaluated the effectiveness of each drug rather than the monotherapies and combination therapy. </p> <p>The results of this analysis indicated that participants receiving amitriptyline either alone or in combination with naproxen exhibited significantly larger improvements in VAS scores of global assessment, pain, sleep difficulty, fatigue,and morning tiredness, and tender point scores. </p> <p>There was no statistically significant effect of naproxen on any of these outcomes.</p> <p>Additionally, participants receiving amitriptyline alone or in combination experienced significant improvements in global assessment, pain, sleep difficulty, fatigue, morning tiredness, and tender point scores between baseline and week six; no statistically significant improvements were seen in participants receiving naproxen monotherapy or placebo. </p> <p>No statistically significant differences in any of the outcome measures were noted between amitriptyline monotherapy and combination therapy. </p> <p>Although eight participants experienced adverse events, none withdrew for this reason. Adverse events experienced were dry mouth (4 participants total in the combination group and the amitriptyline monotherapy group), dyspepsia (1 participant in the naproxen monotherapy group, 1 participant in the placebo group), and diarrhoea (1 participant in the naproxen monotherapy group, and 1 participant in the placebo group). </p> <p>The study authors concluded that amitriptyline monotherapy and amitriptyline in combination with naproxen resulted in significant improvements in all outcome measures compared to placebo treatment. However, the trial did not have the power or sample size to detect any statistically significant differences between amitriptyline monotherapy and combination therapy. As a result of this, the study authors could not determine whether naproxen enhanced the efficacy of amitriptyline. </p> </section> </section> <section id="CD010585-sec-0097"> <h5 class="title">Vlainich 2010</h5> <section id="CD010585-sec-0098"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0099"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0100"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0101"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0102"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest recorded in this study, related to pain, include VAS pain scores, and number of tender points. Adverse events were also reported. </p> <p>VAS pain scores and the number of tender points decreased significantly from baseline to week four of treatment in both groups; however, there were no statistically significant differences in pain scores or the number of tender points between treatment groups. </p> <p>The number of participants experiencing fatigue, subjective edema, and morning stiffness did not change statistically significantly from baseline to week four of treatment in either group or between groups. </p> <p>The number of participants experiencing sleep disorders, paraesthesia, and headache all decreased significantly from baseline to week four within groups, but no significant differences were seen between groups in these measures. </p> <p>Adverse events were not discussed in this report.</p> <p>The study authors concluded that treatment with amitriptyline and lidocaine did not reduce pain significantly more than treatment with amitriptyline alone. </p> </section> </section> </section> <section id="CD010585-sec-0103"> <h4 class="title">Melatonin combined with an antidepressant</h4> <p>We included two studies in this category (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>). </p> <p><a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a> combined both low and high doses of melatonin with fluoxetine and compared them to fluoxetine monotherapy and high‐dose melatonin monotherapy for eight weeks in a four‐group, parallel trial. The number of participants randomised was not specified; 101 participants completed the study and were analyzed. </p> <p><a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>, a recent study, compared the combination of melatonin with amitriptyline to each drug as a monotherapy in a six‐week, three‐group, parallel‐design trial. The study randomised 63 participants and analyzed them on an ITT basis; 57 participants completed the trial. </p> <section id="CD010585-sec-0104"> <h5 class="title">Hussain 2011</h5> <section id="CD010585-sec-0105"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0106"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0107"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0108"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0109"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>The only outcomes recorded in this study were health‐related quality‐of‐life parameters and symptoms parameters on the FIQ. </p> <p>Compared to baseline, FIQ scores were improved by 21.5% in the fluoxetine group, 18.9% in the melatonin monotherapy group, 28.8% in the low‐dose melatonin + fluoxetine group, and 28.9% in the high‐dose melatonin + fluoxetine group; all within‐group comparisons of FIQ scores from baseline were statistically significant. </p> <p>Within‐group comparisons showed that pain scores were significantly reduced by all treatments compared to baseline scores, by: 14.3% in fluoxetine group, 27% in the melatonin group, 27.3% in the low‐dose melatonin + fluoxetine group, and 30% in the high‐dose melatonin + fluoxetine group. </p> <p>Only in both combination groups were all FIQ parameters (pain, fatigue, rest/sleep, stiffness, anxiety, and depression) improved significantly compared to baseline. </p> <p>The presence of adverse events was not mentioned in this study.</p> <p>The study authors concluded that melatonin, alone or in combination, was effective in improving FIQ scores. No statistical comparisons were made between treatment groups in this study, precluding the ability to assess whether combination therapy is superior to monotherapy. </p> </section> </section> <section id="CD010585-sec-0110"> <h5 class="title">de Zanette 2014</h5> <section id="CD010585-sec-0111"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0112"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0113"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0114"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0115"> <h6 class="title">Secondary Outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest related to pain included VAS pain scores, FIQ scores, pressure pain thresholds, number of tender points, and amount of analgesics used in the last week of treatment. Adverse events were also reported. </p> <p>Participants receiving melatonin either alone or in combination had significantly lower VAS pain scores compared to participants receiving amitriptyline monotherapy. </p> <p>Conditioned pain modulation response was tested to assess the function of participants’ descending modulatory systems. Participants receiving melatonin alone or in combination with amitriptyline had significantly reduced pain scores in the conditioned pain modulation task compared to participants receiving amitriptyline monotherapy. </p> <p>A comparison of the change from baseline in FIQ score and pain pressure threshold revealed significantly larger improvements in the combination therapy compared to both monotherapy groups. </p> <p>While all treatments significantly reduced the dose of analgesics, decreased the number of tender points, and improved sleep quality compared to baseline, there were no statistically significant differences between treatments in these outcome measures. </p> <p>Thirteen out of 21 participants in the amitriptyline group, 10/21 in the melatonin monotherapy group, and 9/21 in the combination group experienced adverse events. </p> <p>Adverse events listed were minor (nausea, mild dizziness, weight gain, and dry mouth), or major (severe dizziness, vivid nightmares, crippling drowsiness, severe headache, behavioural changes, and increased pain). </p> <p>The incidence of minor adverse events was significantly lower in the combination group compared to the amitriptyline monotherapy group. </p> <p>The study authors concluded that while all treatments resulted in pain reduction, participants receiving melatonin alone or in combination with amitriptyline experienced slightly larger improvements in pain scores than those receiving amitriptyline monotherapy, and participants receiving combination therapy experienced slight improvements in FIQ scores and pressure pain threshold scores compared to participants receiving either monotherapy. </p> </section> </section> </section> <section id="CD010585-sec-0116"> <h4 class="title">Carisoprodol combined with paracetamol (acetaminophen) and caffeine</h4> <p><a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a> was the only study that compared the combination of carisoprodol, paracetamol (acetaminophen), and caffeine to placebo, in a parallel‐design, eight‐week study. They randomised 58 participants, and 43 participants completed all eight weeks of the trial. </p> <section id="CD010585-sec-0117"> <h5 class="title">Vaeroy 1989</h5> <section id="CD010585-sec-0118"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0119"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0120"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0121"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0122"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest related to pain, that were included in this study, are pressure pain threshold, tender point scores, VAS pain scores, and the use of additional analgesic medication. Adverse events and withdrawals due to lack of efficacy were also reported. </p> <p>Significantly fewer participants in the combination therapy group reported taking additional medication during the trial (4/20), compared to participants in the placebo group (14/23) who took additional medication including analgesics, tricyclic antidepressants, anxiolytics, and sedatives. </p> <p>On VAS scores of pain, sleep quality, and general feeling of sickness, participants in the combination therapy group improved significantly compared to baseline scores, and participants receiving placebo had significantly improved pain and sleep quality scores. </p> <p>Between‐group analyses did not indicate any significant differences between combination therapy and placebo on VAS scores for pain, sleep, or general feeling of sickness. </p> <p>Pressure pain thresholds decreased significantly from baseline in 7 of 10 tender point sites in participants receiving combination therapy, versus only 1/10 in participants in the placebo group (significance not specified, although a 2 x 2 Fisher's Exact test performed on the proportions shows statistical significance). </p> <p>The only adverse event reported was drowsiness, which went away within three to four days of treatment; group allocation was not stated. </p> <p>Three out of 15 withdrawals were a result of lack of efficacy. No information on the treatment group these participants were randomised to was given. </p> <p>The study authors concluded that the combination of carisoprodol, paracetamol (acetaminophen), and caffeine improves pain scores, sleep quality, and general feeling of sickness, in addition to increasing pressure pain thresholds at 7 of 10 tender point sites. However, placebo treatment was also associated with statistically significant improvements in pain scores and sleep quality, although not general feeling of sickness. Moreover, there were no statistically significant differences in VAS pain, sleep quality, and general feeling of sickness scores between treatment groups after eight weeks. The study authors suggested that the improvements in pain and sleep quality seen in the placebo group were likely due to the large amount of extra medication taken by these participants. </p> </section> </section> </section> <section id="CD010585-sec-0123"> <h4 class="title">Tramadol combined with paracetamol (acetaminophen)</h4> <p><a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a> was the only study that tested the combination of tramadol with paracetamol (acetaminophen), comparing this combination to placebo treatment in a 13‐week, parallel‐design trial (). The study randomised 315 participants; 313 participants were analyzed on an ITT basis for treatment efficacy; 312 participants were included in safety analyses. In this study, 175 of 315 participants (56%) withdrew before the final assessment; how the outcomes at the final assessment were made is not clear, but the implication in the paper is that the method was the last observation carried forward, and this can be the source of significant over‐estimation of treatment effects (<a href="./references#CD010585-bbs2-0098" title="MooreRA , StraubeS , EcclestonC , DerryS , AldingtonD , WiffenP , et al. Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses. Pain2012;153(2):265-8. [DOI: 10.1016/j.pain.2011.10.004]">Moore 2012b</a>). </p> <section id="CD010585-sec-0124"> <h5 class="title">Bennett 2003</h5> <section id="CD010585-sec-0125"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Significantly more participants in the combination therapy group (65/156) experienced moderate pain relief (at least a 30% reduction in pain scores) compared to the placebo group (37/157). </p> <p>We judged the quality of evidence for 30% or greater pain relief to be very low. We downgraded the quality of evidence by three levels for indirectness of evidence because the study compared combination pharmacotherapyto placebo only, because imputation where there are high withdrawal rates can lead to very significant over‐estimation of treatment effect, and because of the limited number of events (<a href="./references#CD010585-bbs2-0092" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>; <a href="./references#CD010585-bbs2-0117" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]">Thorlund 2011</a>). </p> </section> <section id="CD010585-sec-0126"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Substantial pain relief (at least a 50% reduction in pain scores) was seen in significantly more participants receiving combination therapy (54/156) compared to participants receiving placebo (29/157). </p> <p>We judged the quality of evidence for 50% or greater pain relief to be very low. We downgraded the quality of evidence by three levels for indirectness of evidence because combination pharmacotherapy was compared to placebo only, because imputation where there are high withdrawal rates can lead to very significant over‐estimation of treatment effect, and because of the limited number of events (<a href="./references#CD010585-bbs2-0092" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>; <a href="./references#CD010585-bbs2-0117" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]">Thorlund 2011</a>). </p> </section> <section id="CD010585-sec-0127"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0128"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0129"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest recorded in this study were time to discontinuation due to lack of efficacy, VAS pain scores, VAS pain relief scores, number of tender points and myalgic scores, FIQ scores, and adverse events. </p> <p>The primary outcome of this study was the time to discontinuation from the study. Significantly more participants in the placebo group discontinued for any reason compared to participants in the combination group (62% versus 48%, respectively). </p> <p>Similarly, significantly more participants taking placebo discontinued due to lack of efficacy (51%) than did participants taking combination therapy (29%). </p> <p>VAS pain scores, pain relief scores, and the number of tender points were significantly lower in the combination therapy group compared to the placebo group, after adjusting for baseline values. </p> <p>Adjusting for baseline values, FIQ score was significantly improved after treatment with combination therapy compared to placebo, as were the scores for the FIQ subscales physical impairment, feel good, do job, pain, rest, stiffness, and anxiety. </p> <p>Similarly, the combination therapy group had significantly better scores on five measures on the SF‐36 (physical functioning, role‐physical, bodily pain, reported health transition, and physical component summary), after adjusting for baseline values. </p> <p>Withdrawal from study participation due to adverse events was noted in 29 of 156 and 18 of 156 participants in the combination group and placebo group, respectively. </p> <p>Significantly more participants in the combination group (118/156) compared to the placebo group (87/156) reported at least one adverse event. </p> <p>The most commonly reported combination treatment‐related side effects were nausea (14), dizziness, somnolence, and constipation (five each); the most common placebo treatment‐related side effects were nausea (seven) and somnolence (five). </p> <p>The study authors concluded that the combination of tramadol and paracetamol (acetaminophen) was moderately effective in reducing pain and pain‐related symptoms of fibromyalgia. </p> </section> </section> </section> <section id="CD010585-sec-0130"> <h4 class="title">Malic acid combined with magnesium</h4> <p><a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a> was the only study that compared the combination of malic acid and magnesium to placebo in a two‐period (four weeks per period), cross‐over design trial (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>). The study randomised 24 participants; they analyzed the 20 participants who completed the study for efficacy; and monitored all 24 participants for adverse events. </p> <section id="CD010585-sec-0131"> <h5 class="title">Russell 1995</h5> <section id="CD010585-sec-0132"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0133"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0134"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0135"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0136"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest included in this study related to pain were VAS pain scores, tender point index, and tender point average. Adverse events were also reported. </p> <p>No statistically significant differences were seen between any outcomes measured during placebo treatment and combination treatment (VAS pain scores, tender point index, tender point average, Health Assessment Questionnaire scores, Center for Epidemiologic Studies Depression scale scores, and anxiety assessed by the Hassle scale scores). </p> <p>Thirteen out of 24 participants reported experiencing at least one adverse event, but no adverse events were considered to be associated with malic acid or magnesium. </p> <p>Combination therapy with malic acid and magnesium did not significantly improve any outcome measures in the blinded trial. However, in a subsequent open‐label trial in which 18 participants were given higher doses for a longer period of time, pain and tender point index scores were significantly reduced compared to baseline values. </p> <p>The study authors concluded that although the blinded trial did not show superiority of combination therapy over placebo, results from the open‐label study suggested that pain symptoms were improved when malic acid and magnesium were given at a higher dose for a longer treatment period. </p> </section> </section> </section> <section id="CD010585-sec-0137"> <h4 class="title">Monoamine oxidase inhibitor (MAOI) combined with 5‐hydroxytryptophan (5‐HTP)</h4> <p><a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a> was the only study that evaluated the efficacy of the MAOI paragyline or phenelzine alone, 5‐HTP alone, the combination of these two classes of agents, and amitriptyline alone in a 12‐month, parallel‐design trial. No information was given on the number of participants randomised; 200 participants were analyzed. </p> <section id="CD010585-sec-0138"> <h5 class="title">Nicolodi 1996</h5> <section id="CD010585-sec-0139"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0140"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0141"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0142"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0143"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>One secondary outcome related to pain reported was VAS pain scores. Adverse events were also reported. </p> <p>All treatments resulted in significantly reduced pain scores compared to baseline scores when compared within groups. </p> <p>The study authors stated that the improvement in pain scores was significantly greater in participants receiving combination therapy compared to monotherapy or treatment with amitriptyline; however, these analyses were not shown. </p> <p>No participants experiencing side effects withdrew from the study; no side effects reported were considered to be severe. </p> <p>The most commonly reported adverse events were stiffness (9.5%) and nausea (9.5%) during the placebo pretreatment period, stomach‐ache (8%) and insomnia (6%) in the MAOI group, stomach‐ache (8%) in both the 5‐HTP group and the combination therapy group, and drowsiness (20%) and dizziness (6%) in the amitriptyline group. </p> <p>The study authors concluded that combination therapy of an MAOI plus 5‐HTP was more effective in reducing pain compared to each monotherapy and amitriptyline therapy. </p> </section> </section> </section> <section id="CD010585-sec-0144"> <h4 class="title">Pregabalin combined with duloxetine</h4> <p><a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a> was the only study that examined the efficacy of a combination of pregabalin and duloxetine in the treatment of fibromyalgia, compared to each drug alone, and to placebo alone in a four‐period (6 weeks per period) cross‐over design trial. The study randomised 41 participants and included them in adverse effects analyses; the 39 participants who completed at least two treatment periods were included in efficacy analyses. </p> <section id="CD010585-sec-0145"> <h5 class="title">Gilron 2016</h5> <section id="CD010585-sec-0146"> <h6 class="title">Patient‐reported pain relief of 30% or greater</h6> <p>Combination therapy produced a 28% reduction in pain scores from baseline, which was significantly larger than that produced by pregabalin monotherapy (1.4%) and placebo (7.1%). </p> <p>Statistically significant differences in the proportion of participants experiencing at least moderate global pain relief were seen in comparisons between combination therapy (68%) versus each monotherapy (42% pregabalin and 39% duloxetine) and versus placebo (18%), and between duloxetine monotherapy versus placebo. </p> <p>We judged the quality of evidence for 30% or greater pain relief to be very low. We downgraded the quality of evidence by three levels for indirectness of evidence because of the limited number of participants (39 providing data) and events in this multiple cross‐over study (<a href="./references#CD010585-bbs2-0092" title="MooreRA , GavaghanD , TramèrMR , CollinsSL , McQuayHJ . Size is everything - large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects. Pain1998;78(3):209-16. [DOI: 10.1016/S0304-3959(98)00140-7]">Moore 1998</a>; <a href="./references#CD010585-bbs2-0117" title="ThorlundK , ImbergerG , WalshM , ChuR , GluudC , WetterslevJ , et al. The number of patients and events required to limit the risk of overestimation of intervention effects in meta-analysis--a simulation study. PLoS One2011;6(10):e25491. [DOI: 10.1371/journal.pone.0025491]">Thorlund 2011</a>). </p> </section> <section id="CD010585-sec-0147"> <h6 class="title">Patient‐reported pain relief of 50% or greater</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0148"> <h6 class="title">Patient‐reported global impression of clinical change much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0149"> <h6 class="title">Patient‐reported global impression of clinical change very much improved</h6> <p>Results were not reported for this outcome. We judged the quality of evidence for this outcome to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> </section> <section id="CD010585-sec-0150"> <h6 class="title">Secondary outcomes</h6> <p>We judged the quality of evidence for all secondary outcomes to be very low. We downgraded the quality of evidence by three levels due to lack of data. </p> <p>Secondary outcomes of interest reported were VAS pain scores, worst pain intensity over the last 24 hours, nocturnal pain intensity, global pain relief scores, SF‐MPQ scores, FIQ scores, Brief Pain Inventory (BPI) scores, number of tender points, and adverse events. </p> <p>The primary outcome in the trial was pain intensity over the past 24 hours, averaged across the seven days during which participants received their maximal tolerated dose (MTD) of study drug(s). Pain was significantly reduced by both the combination treatment and the duloxetine monotherapy compared to placebo and to pregabalin monotherapy. Pain did not differ significantly between combination therapy and duloxetine monotherapy, or between pregabalin monotherapy and placebo. Worst pain on a scale from 0 to 10 in the past 24 hours, averaged across seven days at MTD, was significantly lower during combination therapy (4.5) compared to placebo (6.0) and pregabalin monotherapy (5.9), but did not differ statistically significantly from that reported during duloxetine monotherapy (4.8). Similarly, nocturnal pain was significantly lower during combination therapy (3.2) compared to placebo (4.4) and pregabalin monotherapy (4.2), but did not differ statistically significantly from that reported during duloxetine monotherapy (3.8). </p> <p>There were no statistically significant differences in the number of tender points between the treatment groups. </p> <p>Combination therapy was associated with significantly improved SF‐MPQ, FIQ, and SF‐36 scores compared to both monotherapy treatments and to placebo. </p> <p>Medical Outcomes Study Sleep Scale scores were significantly improved with combination therapy compared to placebo and duloxetine monotherapy. </p> <p>Adverse events were reported during each treatment. At MTD, the frequency of two adverse events differed significantly based on treatment. Drowsiness occurred significantly more frequently during combination therapy (26.5%) compared to duloxetine monotherapy (5.3%) and placebo treatment (5.3%), and insomnia was reported significantly more often by participants taking placebo (34.2%) compared to those taking combination therapy (11.8%) and those taking pregabalin monotherapy (7.9%). </p> <p>Participants who withdrew from the study were given the option to withdraw from their current treatment and start the next randomised treatment. Withdrawals due to adverse events occurred during placebo treatment (one participant), pregabalin monotherapy (one participant), duloxetine monotherapy (three participants), and combination therapy (two participants). Of these participants, three chose to continue with the next treatment period (two who withdrew from duloxetine monotherapy, and one who withdrew from combination therapy). </p> <p>There were no statistically significant differences in the number of tender points between the treatment groups. </p> <p>Combination therapy was associated with significantly improved SF‐MPQ, FIQ, and SF‐36 scores compared to both monotherapy treatments and to placebo. </p> <p>Medical Outcomes Study Sleep Scale scores were significantly improved with combination therapy compared to placebo and duloxetine monotherapy. </p> <p>Adverse events were reported during each treatment.</p> <p>At MTD, the frequency of two adverse events differed significantly based on treatment. Drowsiness occurred significantly more frequently during combination therapy (26.5%) compared to duloxetine monotherapy (5.3%) and placebo treatment (5.3%), and insomnia was reported significantly more often by participants taking placebo (34.2%) compared to those taking combination therapy (11.8%) and those taking pregabalin monotherapy (7.9%). </p> <p>Participants who withdrew from the study were given the option to withdraw from their current treatment and start the next randomised treatment. </p> <p>Withdrawals due to adverse events occurred during placebo treatment (one participant), pregabalin monotherapy (one participant), duloxetine monotherapy (three participants), and combination therapy (two participants). Of these participants, three chose to continue with the next treatment period (two who withdrew from duloxetine monotherapy, and one who withdrew from combination therapy). </p> <p>Adverse events were reported during each treatment.</p> <p>At MTD, the frequency of two adverse events differed significantly based on treatment. Drowsiness occurred significantly more frequently during combination therapy (26.5%) compared to duloxetine monotherapy (5.3%) and placebo treatment (5.3%), and insomnia was reported significantly more often by participants taking placebo (34.2%) compared to those taking combination therapy (11.8%) and those taking pregabalin monotherapy (7.9%). </p> <p>Participants who withdrew from the study were given the option to withdraw from their current treatment and start the next randomised treatment. </p> <p>Withdrawals due to adverse events occurred during placebo treatment (one participant), pregabalin monotherapy (one participant), duloxetine monotherapy (three participants), and combination therapy (two participants). Of these participants, three chose to continue with the next treatment period (two who withdrew from duloxetine monotherapy, and one who withdrew from combination therapy). </p> <p>Participants who withdrew from the study were given the option to withdraw from their current treatment and start the next randomised treatment. </p> <p>Withdrawals due to adverse events occurred during placebo treatment (one participant), pregabalin monotherapy (one participant), duloxetine monotherapy (three participants), and combination therapy (two participants). Of these participants, three chose to continue with the next treatment period (two who withdrew from duloxetine monotherapy, and one who withdrew from combination therapy). </p> </section> </section> </section> <section id="CD010585-sec-0151"> <h4 class="title">Meta‐analyses</h4> <p>We did not conduct meta‐analyses of the trials investigating combinations of NSAIDs and benzodiazepines (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>), amitriptyline and fluoxetine (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>), or melatonin and antidepressants (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>). These studies did not report data on the primary outcomes of interest to this review (individual participant‐level data on pain relief or global impression of change), and there were many sources of heterogeneity (for example, different drugs, dosages, and participant populations used) that precluded the validity of meta‐analysis. </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD010585-sec-0152" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD010585-sec-0152"></div> <section id="CD010585-sec-0153"> <h3 class="title" id="CD010585-sec-0153">Summary of main results</h3> <p>Sixteen studies met our criteria to be included in this systematic review. Given how common combination pharmacotherapy is for the treatment of fibromyalgia (<a href="./references#CD010585-bbs2-0058" title="BergerA , DukesE , MartinS , EdelsbergJ , OsterG . Characteristics and healthcare costs of patients with fibromyalgia syndrome. International Journal of Clinical Practice2007;61(9):1498-508.">Berger 2007</a>), it is surprising that there are few high‐quality randomised controlled trials comparing the efficacy of combination pharmacotherapy with monotherapy at reducing pain in people with fibromyalgia. Only nine included studies compared combination pharmacotherapy with each monotherapy (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). The remaining five studies compared combination pharmacotherapy with only one monotherapy (<a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>) or with inactive placebo (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). </p> <p>Overall, there was very little evidence to support or refute the hypothesis that combination pharmacotherapy is superior to monotherapy for treating fibromyalgia pain. In particular, there was little to no data on the specific outcomes of this review (pain relief 30% or greater, pain relief 50% or greater, global impression of clinical change much or very much improved, any pain‐related outcome indicating some improvement, any adverse event, any serious adverse event, withdrawals due to adverse event). The limited number of studies comparing combination therapy with all monotherapies (9/16 identified for this review), the small sample sizes employed (50 or more per treatment arm in most cases), and the relatively short duration of each trial (6 weeks or less in most cases) diminishes our ability to draw firm conclusions. There were some studies assessing similar drug combinations, but meta‐analyses were precluded due to variable dosing, medications, and outcomes. </p> <p>The heterogeneity between included trials makes it difficult to summarise the findings about adverse events reported by participants taking placebo, monotherapy, or combination pharmacotherapy. However, in the 12 studies that reported adverse events, none reported serious adverse events, and there was no clear preponderance of adverse events in combination pharmacotherapy groups versus monotherapy groups (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Therefore, based upon the current evidence, there is no evidence of harm with the use of combination pharmacotherapy compared to monotherapy in the treatment of fibromyalgia. However, the quality of the evidence is very low, and therefore new studies will likely change the conclusions that can be drawn. Moreover, since adverse events are specific to the drug(s) being taken, this conclusion cannot be generalised to all combination pharmacotherapies for fibromyalgia; safety and tolerability of each combination must be examined in comparison to its individual components. </p> </section> <section id="CD010585-sec-0154"> <h3 class="title" id="CD010585-sec-0154">Overall completeness and applicability of evidence</h3> <p>We cannot draw a firm conclusion that all combination therapies are superior or inferior to monotherapies for fibromyalgia. </p> <p>We grouped the 16 included studies in this review into eight categories based on the class of drugs evaluated. </p> <p> <ul id="CD010585-list-0008"> <li> <p>NSAIDs + benzodiazepines (<a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>); </p> </li> <li> <p>Celecoxib + famciclovir (<a href="./references#CD010585-bbs2-0010" title="PridgenWL , DuffyC , GendreauJF , GendreauRM . A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. Journal of Pain Research2017;10:451-60. ">Pridgen 2017</a>); </p> </li> <li> <p>Amitriptyline + fluoxetine (<a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>); </p> </li> <li> <p>Amitriptyline + another agent (<a href="./references#CD010585-bbs2-0001" title="Albertoni GiraldesAL , SalomãoR , LealPD , BrunialtiMK , SakataRK . Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: a randomized double-blind study. International Journal of Rheumatic Diseases2016;19(10):946-53. ">Albertoni Giraldes 2016</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>); </p> </li> <li> <p>Melatonin + amitriptyline (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>); </p> </li> <li> <p>Carisoprodol + paracetamol (acetaminophen) + caffeine (<a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>); </p> </li> <li> <p>Tramadol + paracetamol (acetaminophen) (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>); </p> </li> <li> <p>Malic acid + magnesium (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>); </p> </li> <li> <p>MAOI + 5‐HT (<a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>); and </p> </li> <li> <p>Pregabalin + duloxetine (<a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>). </p> </li> </ul> </p> <p>There was conflicting evidence in the NSAIDs + benzodiazepines subgroup. <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a> found improvements in tender point index and participant‐rated pain scores when comparing the combination of ibuprofen and alprazolam with placebo treatment, but not with each monotherapy. On the other hand, <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a> found some improvements after combination tenoxicam‐bromazepam therapy compared to bromazepam monotherapy (number of tender points) or tenoxicam monotherapy (marked improvement or asymptomatic rating given to the global status of disease), but no difference between combination therapy and placebo treatment. Finally, <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a> concluded that alprazolam and ibuprofen monotherapies were slightly better than the combination of these drugs in reducing fibromyalgia symptoms. </p> <p>Other subgroups (carisoprodol + paracetamol (acetaminophen) + caffeine, tramadol + paracetamol (acetaminophen), and amitriptyline + fluoxetine) provided evidence to support combination pharmacotherapy, but included studies that only compared combination therapy to inactive placebo (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>) or one monotherapy alone (<a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). Still other subgroups (melatonin + antidepressant, and MAOIs + 5‐HTP) included studies that provided inconclusive data due to lack of statistical comparisons between groups (<a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). </p> <p>Finally, two subgroups included studies that provided no evidence for superiority of combination therapy over monotherapy (malic acid + magnesium, and amitriptyline + another drug), but only compared combinations with inactive placebo (<a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>) or one monotherapy (<a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>). The remaining studies either provided support for (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>) or against (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>) combination pharmacotherapy over monotherapy, and all studies compared distinct combinations. We cannot draw firm conclusions for any combination due to the limited number of studies examining each combination with each monotherapy, the small sample sizes, and the short trial durations. There was considerable variability between trials in terms of inclusion and exclusion criteria. But the most relevant of these was the criteria used for diagnosing fibromyalgia in potential study participants. Nine trials used the 1990 ACR criteria (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>; <a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a>; <a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a>; <a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a>; <a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a>). One trial used the updated 2010 ACR criteria, which are broader (<a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a>). Three trials used criteria outlined in <a href="./references#CD010585-bbs2-0126" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a> (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). One trial did not use published guidelines, but reported that 76 out of 78 participants met the <a href="./references#CD010585-bbs2-0126" title="YunusM , MasiAT , CalabroJJ , MillerKA , FeigenbaumSL . Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Seminars in Arthritis and Rheumatism1981;11(1):151-71.">Yunus 1981</a> criteria (<a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>). It is possible that these differences in fibromyalgia diagnostic criteria between studies contributed to variability in study results. </p> </section> <section id="CD010585-sec-0155"> <h3 class="title" id="CD010585-sec-0155">Quality of the evidence</h3> <p>Although most studies had unclear or low risk of bias for issues related to randomisation and blinding, there were several issues with the quality of many of the included studies in this review. Two studies made conclusions that were not clearly supported by their statistical analyses (<a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a>). Most studies had an unclear or high risk of bias due to small sample sizes (fewer than 50 participants per arm) or short trial durations (7 weeks or less), or both. Most studies (11/16) used a parallel design (the remaining three used a cross‐over design), leading to limited power especially given that most of these parallel‐design studies also had small sample sizes and short durations. Several of the included studies are old and therefore did not use the 1990 (or 2010) ACR diagnostic criteria for fibromyalgia, indicating that some of the participants in these studies may not meet the diagnostic criteria for fibromyalgia today (<a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>). Imputation methods may have been an issue with some studies. For example, for one large 13‐week study, the withdrawal rate was 56% (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>). </p> <p>While not strictly a matter of quality, the lack of studies comparing each monotherapy separately and combined was surprising. </p> <p>Although they met our criteria for inclusion, five out of 16 included studies only compared combination treatment to one monotherapy or to placebo alone. This tremendously limits our ability to conclude anything about the superiority or inferiority of combination therapy to monotherapy. </p> <p>Our GRADE assessments were consequently very low for primary outcomes of pain relief of 30% or 50% or greater, PGIC very much or much or very much improved, any pain‐related outcome, participants experiencing any adverse event, any serious adverse event, or withdrawing because of an adverse event. This was a result of a number of factors, including heterogeneity among studies in terms of class of agents evaluated, specific combinations used, outcomes reported, and doses given prevented any meta‐analysis; none of the combinations of drugs found provided sufficient data for analysis compared with placebo or other comparators for our preferred outcomes. </p> </section> <section id="CD010585-sec-0156"> <h3 class="title" id="CD010585-sec-0156">Potential biases in the review process</h3> <p>We do not believe there is a substantial risk for bias in our review process. We had fairly liberal inclusion criteria, avoiding exclusion of studies on the basis of the language they were published in alone. The only risk for bias in the review process is that related to publication bias: trials may be more likely to be published if they have a positive result. It is therefore possible that data showing no difference between combination therapies and monotherapies exist, but are not accessible because they are not published. Our search did include some studies with negative results, and the clinical question is of great importance for fibromyalgia, and we judge that unpublished studies are a large source of bias in our review. </p> </section> <section id="CD010585-sec-0157"> <h3 class="title" id="CD010585-sec-0157">Agreements and disagreements with other studies or reviews</h3> <p>There are many reviews on pharmacotherapy for the treatment of fibromyalgia, but few focus on the specific topic of whether or not combination pharmacotherapy is superior to monotherapy for treating fibromyalgia. Some broader reviews include a comment on combination therapy for fibromyalgia, stating that despite the paucity of evidence to support it, polypharmacy is necessary to alleviate discomfort in many participants because fibromyalgia is a multifaceted disease with diverse symptoms (<a href="./references#CD010585-bbs2-0060" title="CalandreEP , Rico-VillademorosF , SlimM . An update on pharmacotherapy for the treatment of fibromyalgia. Expert Opinion on Pharmacotherapy2015;16(9):1347-68.">Calandre 2015</a>; <a href="./references#CD010585-bbs2-0067" title="DaleR , StaceyB . Multimodal treatment of chronic pain. Medical Clinics of North America2016;100:55-64.">Dale 2016</a>; <a href="./references#CD010585-bbs2-0071" title="GerardiMC , BatticciottoA , TalottaR , Di FrancoM , AtzeniF , Sarzi-PuttiniP . Novel pharmaceutical options for treating fibromyalgia. Expert Review of Clinical Pharmacology2016;9(4):559-65.">Gerardi 2016</a>; <a href="./references#CD010585-bbs2-0076" title="HanC , Lee S-J, Seo H-J, Wang S-M, Park M-H, PatkarAA , et al. Available therapies and current management of fibromyalgia: focusing on pharmacologic agents. Drugs of Today2011;47(7):539-57.">Han 2011</a>). <a href="./references#CD010585-bbs2-0091" title="MeasePJ , SeymourK . Fibromyalgia: should the treatment paradigm be monotherapy or combination pharmacotherapy?Current Pain and Headache Reports2008;12(6):399-405.">Mease 2008</a> reviewed several promising monotherapies for the treatment of fibromyalgia, but also provided the rationale for combination therapy, citing two of our included studies (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>), and proposed a trial design to test the question of whether medications can act synergistically or additively to reduce fibromyalgia symptoms safely. In a more recent review on combination versus monotherapy, <a href="./references#CD010585-bbs2-0059" title="CalandreEP , Rico-VillademorosF , Rodriguez-LopezCM . Monotherapy or combination therapy for fibromyalgia treatment?Current Rheumatology Reports2012;14:568-75.">Calandre 2012</a> cites 10 studies that examine the efficacy of combination pharmacotherapy; six of these studies are also included in our review (<a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a>; <a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a>; <a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a>; <a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a>; <a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a>; <a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a>), while the other four are open‐label trials that were also identified in our search and excluded. No meta‐analyses were undertaken since this was simply a narrative review; however, their conclusions are similar to our own: there is some evidence to suggest that combination pharmacotherapy may be superior to monotherapy, but more research on specific drug combinations is needed due to the current lack of studies on the topic. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD010585-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/urn:x-wiley:14651858:media:CD010585:CD010585-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Flow diagram" data-id="CD010585-fig-0001" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_t/tCD010585-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010585-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/urn:x-wiley:14651858:media:CD010585:CD010585-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study" data-id="CD010585-fig-0002" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_t/tCD010585-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD010585-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/urn:x-wiley:14651858:media:CD010585:CD010585-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies" data-id="CD010585-fig-0003" src="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_t/tCD010585-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/media/CDSR/CD010585/image_n/nCD010585-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD010585-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with fibromyalgia </p> <p><b>Settings:</b> community </p> <p><b>Intervention:</b> any combination of two or more drugs (note: our searches found nine combinations of drugs) </p> <p><b>Comparison:</b> placebo and/or other comparators </p> </td> </tr> <tr class="separated"> <th align="center" class="headercell" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Outcome</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>Result</b> </p> </th> <th align="center" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="middle"> <p><b>GRADE</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported pain relief of 30% or greater</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported pain relief of 50% or greater</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Patient‐reported global impression of clinical change much or very much improved (moderate improvement) </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Any pain‐related outcome indicating some improvement</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants experiencing any serious adverse event</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrawals due to adverse events</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>No or insufficient data for analysis for any combination of drugs</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Very low quality, as no data for analysis</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="3" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/><b>High quality:</b> we are very confident that the true effect lies close to that of the estimate of the effect<br/><b>Moderate quality:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of effect, but there is a possibility that it is substantially different<br/><b>Low quality:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect<br/><b>Very low quality:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Any combination of two or more drugs compared with placebo or other comparators, or both, for fibromyalgia</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD010585-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methodology of included trials</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign=""> <p><b>First author, year</b> </p> </th> <th align="center" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Trial comparisons</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Placebo‐controlled</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. only 1 component</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. both components</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Combination vs. other</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0001" title="Albertoni GiraldesAL , SalomãoR , LealPD , BrunialtiMK , SakataRK . Effect of intravenous lidocaine combined with amitriptyline on pain intensity, clinical manifestations and the concentrations of IL-1, IL-6 and IL-8 in patients with fibromyalgia: a randomized double-blind study. International Journal of Rheumatic Diseases2016;19(10):946-53. ">Albertoni Giraldes 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0002" title="BennettRM , KaminM , KarimR , RosenthalN . Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain: a double-blind, randomized, placebo-controlled study. American Journal of Medicine2003;114(7):537-45. BennettRM , ScheinJ , KosinskiMR , HewittDJ , JordanDM , RosenthalNR . Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis and Rheumatology2005;4:519-27. ">Bennett 2003</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0003" title="deZanetteSA , VercelinoR , LasteG , RoziskyJR , SchwertnerA , MachadoCB , et al. Melatonin analgesia is associated with improvement of the descending endogenous pain-modulating system in fibromyalgia: a phase II, randomized, double-dummy, controlled trial. BMC Pharmacology and Toxicology2014;15:1-14. ">de Zanette 2014</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0004" title="GilronI , ChaparroLE , TuD , HoldenRR , MilevR , TowheedT , et al. Combination of pregabalin with duloxetine for fibromyalgia. Pain2016;157:1532-40. ">Gilron 2016</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0005" title="GoldenbergDL , FelsonDT , DinermanH . A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis and Rheumatism1986;29(11):1371-7. ">Goldenberg 1986</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0006" title="GoldenbergDL , MayskiyM , MosseyC , RuthazerR , SchmidC . A randomized, double-blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis and Rheumatism1996;39(11):1852-9. ">Goldenberg 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0007" title="HussainSAR , Al-KhalifaII , JasimNA , GorialFI . Adjuvant use of melatonin for treatment of fibromyalgia. Journal of Pineal Research2011;50(3):267-71. ">Hussain 2011</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0008" title="KravitzHM , KatzRS , HelmkeN , JeffriessH , BukovskyJ , FawcettJ . Alprazolam and ibuprofen in the treatment of fibromyalgia – report of a double-blind placebo-controlled study. Journal of Musculoskeletal Pain1994;2(1):3-27. ">Kravitz 1994</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+<sup>a</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0010" title="PridgenWL , DuffyC , GendreauJF , GendreauRM . A famciclovir + celecoxib combination treatment is safe and efficacious in the treatment of fibromyalgia. Journal of Pain Research2017;10:451-60. ">Pridgen 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0011" title="Quijada-CarreraJ , Valenzuela-CastañoA , Povedano-GómezJ , Fernández-RodriguezA , Hernánz-MedianoW , Gutierrez-RubioA , et al. Comparison of tenoxicam and bromazepam in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled trial. Pain1996;65(2):221-5. ">Quijada‐Carrera 1996</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0012" title="RussellIJ , FletcherEM , MichalekJE , McBroomPC , HesterGG . Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam. A double-blind, placebo-controlled study. Arthritis and Rheumatism1991;34(5):552-60. ">Russell 1991</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0013" title="RussellIJ , MichalekJE , FlechasJD , AbrahamGE . Treatment of fibromyalgia syndrome with Super Malic®: a randomized, double blind, placebo controlled, crossover pilot study. Journal of Rheumatology1995;22(5):953-8. ">Russell 1995</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0014" title="VaerøyH , AbrahamsenA , Førre Ø, KåssE . Treatment of fibromyalgia (fibrositis syndrome): a parallel double blind trial with carisoprodol, paracetamol and caffeine (Somadril comp®) versus placebo. Clinical Rheumatology1989;8(2):245-50. ">Vaeroy 1989</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0015" title="VlainichR , IssyAM , GerolaLR , SakataRK . Effect of intravenous lidocaine on manifestations of fibromyalgia. Pain Practice2010;10(4):301-5. VlainichR , IssyAM , SakataRK . Effect of intravenous lidocaine associated with amitriptyline on pain relief and plasma serotonin, norepinephrine, and dopamine concentrations in fibromyalgia. Clinical Journal of Pain2011;27(4):285-8. ">Vlainich 2010</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><a href="./references#CD010585-bbs2-0016" title="ZuckerDR , RuthazerR , SchmidCH , FeuerJM , FischerPA , KievalRI , et al. Lessons learned combining N-of-1 trials to assess fibromyalgia therapies. Journal of Rheumatology2006;33(10):2069-77. ">Zucker 2006</a> </p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>+</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p><sup>a</sup><a href="./references#CD010585-bbs2-0009" title="NicolodiM , SicuteriF . Fibromyalgia and migraine, two faces of the same mechanism. Recent Advances in Tryptophan Research1996;398:373-9. ">Nicolodi 1996</a> compared a monoamine oxidase inhibitor, 5‐hydroxytryptophan, their combination, and amitriptyline. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Methodology of included trials</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD010585.pub2/full#CD010585-tbl-0002">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD010585.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD010585-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD010585-note-0006">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD010585-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD010585-note-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD010585-note-0005">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD010585-note-0004">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010585\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010585\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010585\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD010585\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD010585\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=PrHmaMrX&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010585.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD010585.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD010585.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD010585.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD010585.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740725675958"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010585.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740725675961"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD010585.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e810b79d6f466',t:'MTc0MDcyNTY3Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 